PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 34299013-3 2021 Here, we show that IL-10-deficient mice treated with piroxicam exhibited significant alterations of the intestinal barrier function, including permeability, inflammation-related bioactive lipid mediators, and mucosal CD4+ T lymphocyte subsets. Piroxicam 53-62 interleukin 10 Mus musculus 19-24 34299013-3 2021 Here, we show that IL-10-deficient mice treated with piroxicam exhibited significant alterations of the intestinal barrier function, including permeability, inflammation-related bioactive lipid mediators, and mucosal CD4+ T lymphocyte subsets. Piroxicam 53-62 CD4 antigen Mus musculus 217-220 35190960-5 2022 Serum content of IgG, IL-2, and IL-10 reduced in the Piroxicam group, whereas IgG, TNF-alpha, and IL-6 increased in the Piroxicam group in comparison to the other groups. Piroxicam 120-129 tumor necrosis factor Mus musculus 83-92 35168147-5 2022 Flurbiprofen/naproxen and piroxicam are located in the active site and the primary binding site of CYP2C9, respectively. Piroxicam 26-35 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 99-105 35190960-5 2022 Serum content of IgG, IL-2, and IL-10 reduced in the Piroxicam group, whereas IgG, TNF-alpha, and IL-6 increased in the Piroxicam group in comparison to the other groups. Piroxicam 120-129 interleukin 6 Mus musculus 98-102 35190960-6 2022 Myeloperoxidase activity witnessed a significant increase in the Piroxicam group compared with the other groups. Piroxicam 65-74 myeloperoxidase Mus musculus 0-15 35190960-13 2022 TNF-alpha and IL-6 genes had significantly upregulated in the colon of the Piroxicam group compared to the control group, while they were significantly downregulated in the SB group. Piroxicam 75-84 tumor necrosis factor Mus musculus 0-9 35190960-13 2022 TNF-alpha and IL-6 genes had significantly upregulated in the colon of the Piroxicam group compared to the control group, while they were significantly downregulated in the SB group. Piroxicam 75-84 interleukin 6 Mus musculus 14-18 35190960-14 2022 In contrast, IL-2 and IL-10 genes had upregulated in the colon of the SB group compared to the control groups, while they had downregulated in the Piroxicam group. Piroxicam 147-156 interleukin 2 Mus musculus 13-17 35190960-14 2022 In contrast, IL-2 and IL-10 genes had upregulated in the colon of the SB group compared to the control groups, while they had downregulated in the Piroxicam group. Piroxicam 147-156 interleukin 10 Mus musculus 22-27 35186102-0 2022 Jianpi Qingchang Decoction Ameliorates Chronic Colitis in Piroxicam-Induced IL-10 Knockout Mice by Inhibiting Endoplasmic Reticulum Stress. Piroxicam 58-67 interleukin 10 Mus musculus 76-81 35186102-14 2022 The results showed that JPQCD significantly reduced body weight loss, ameliorated disease activity index, and restored colon length in IL-10 -/- mice with piroxicam-induced colitis. Piroxicam 155-164 interleukin 10 Mus musculus 135-140 2526851-4 1989 The suppressive activity was mediated by PGE2 as demonstrated by direct PGE2 determination in CD8+ cell free supernatants, and by inhibition of CD8+ cell suppression with indomethacin or piroxicam in vitro. Piroxicam 187-196 CD8a molecule Homo sapiens 144-147 2473337-4 1989 However, when indomethacin or piroxicam was administered between two doses of ET-1 or ET-3, the second response was significantly potentiated. Piroxicam 30-39 endothelin 1 Rattus norvegicus 78-90 16666890-7 1989 Both NSE and SE-induced lipoxygenase was inhibited by piroxicam in vitro. Piroxicam 54-63 linoleate 9S-lipoxygenase A Solanum lycopersicum 24-36 2475790-4 1989 If the secretory state of piroxicam treated tissues was restored by addition of either forskolin, vasoactive intestinal polypeptide (VIP), prostaglandin E2 (PGE2) or isobutyl-1-methyl-xanthine (IBMX) then subsequent additions of xylazine were effective in reducing SCC. Piroxicam 26-35 vasoactive intestinal peptide Rattus norvegicus 98-131 2475790-4 1989 If the secretory state of piroxicam treated tissues was restored by addition of either forskolin, vasoactive intestinal polypeptide (VIP), prostaglandin E2 (PGE2) or isobutyl-1-methyl-xanthine (IBMX) then subsequent additions of xylazine were effective in reducing SCC. Piroxicam 26-35 vasoactive intestinal peptide Rattus norvegicus 133-136 2547713-4 1989 Piroxicam therapy had no effect on PMN random migration and phagocytosis, while it significantly reduced both FMLP-induced aggregation and FMLP-induced chemotaxis. Piroxicam 0-9 formyl peptide receptor 1 Homo sapiens 139-143 2547713-6 1989 In contrast, a marked impairment of NBT test and PMA- and FMLP-induced superoxide anion (O2-) production was found after piroxicam therapy. Piroxicam 121-130 formyl peptide receptor 1 Homo sapiens 58-62 2474512-3 1989 In contrast piroxicam increased ALU-CFA-induced suppression of autoantibodies against myelin basic protein. Piroxicam 12-21 myelin basic protein Rattus norvegicus 86-106 2968844-2 1988 IL-1 production was initially studied in the presence of piroxicam and indomethacin, both inhibitors of prostaglandin biosynthesis. Piroxicam 57-66 interleukin 1 complex Mus musculus 0-4 2464161-4 1988 Data presented here shows that NPY responsiveness is restored, in piroxicam pretreated tissues, by vasoactive intestinal polypeptide (VIP), forskolin, prostaglandin E2 (PGE2) isobutyl-1-methyl-xanthine (IBMX) and dibutyryl cAMP added prior to the neuropeptide. Piroxicam 66-75 neuropeptide Y Rattus norvegicus 31-34 3392683-17 1988 The cyclo-oxygenase inhibitors piroxicam (5 microM) and indomethacin (5 microM) significantly reduced the responses to both NPY and PYY in rat jejunum. Piroxicam 31-40 neuropeptide Y Rattus norvegicus 124-127 3392683-17 1988 The cyclo-oxygenase inhibitors piroxicam (5 microM) and indomethacin (5 microM) significantly reduced the responses to both NPY and PYY in rat jejunum. Piroxicam 31-40 peptide YY Rattus norvegicus 132-135 3032795-5 1987 Studies showed that four and 10 weeks of piroxicam therapy resulted in significantly suppressed neutrophil O2- production in response to phorbol myristate acetate (PMA) and formyl methionyl leucyl phenylalanine (FMLP). Piroxicam 41-50 formyl peptide receptor 1 Homo sapiens 212-216 2828616-1 1987 The antiinflammatory agent piroxicam caused dose dependent inhibition of N-formylmethionyl-leucyl-phenylalanine (FMLP) induced monocyte superoxide release in vitro, but had no effect on the response to serum treated zymosan, phorbol myristate acetate or the calcium ionophore A23187. Piroxicam 27-36 formyl peptide receptor 1 Homo sapiens 113-117 3673588-1 1987 A selective zymosan-induced release of lysozyme from freshly prepared human blood granulocytes and monocytes was inhibited by indomethacin, sulindac, piroxicam and ibuprofen. Piroxicam 150-159 lysozyme Homo sapiens 39-47 3611284-2 1987 The method uses a reversed-phase C18 column with pH 3 aqueous buffer/methanol, 55:45, v/v mobile phase, and is selective for piroxicam in the presence of other "oxicams," synthetic precursors, by-products, degradation products, metabolites, and related compounds. Piroxicam 125-134 Bardet-Biedl syndrome 9 Homo sapiens 33-36 3037033-8 1987 In the 12 patients who received MVP plus piroxicam, PHA and IL-2 assays improved by days 7-14 and indomethacin-regulation was normal; moreover, this improvement persisted throughout the 21-day treatment cycle. Piroxicam 41-50 interleukin 2 Homo sapiens 60-64 3828657-13 1987 Both piroxicam and indomethacin inhibited the increase in SCC elicited by AII in the jejunum, and the reduction in SCC caused by AII in the colon. Piroxicam 5-14 angiotensinogen Rattus norvegicus 74-77 3828657-13 1987 Both piroxicam and indomethacin inhibited the increase in SCC elicited by AII in the jejunum, and the reduction in SCC caused by AII in the colon. Piroxicam 5-14 angiotensinogen Rattus norvegicus 129-132 3493347-4 1986 A variable effect of piroxicam was observed on IL-1 and IL-2 generation despite the efficacy of piroxicam in reducing the clinical activity of the disease. Piroxicam 21-30 interleukin 1 alpha Homo sapiens 47-51 3493347-4 1986 A variable effect of piroxicam was observed on IL-1 and IL-2 generation despite the efficacy of piroxicam in reducing the clinical activity of the disease. Piroxicam 21-30 interleukin 2 Homo sapiens 56-60 6493354-5 1984 The displacement of piroxicam (in the therapeutical concentration of 4.5 x 10(5) mol/l) from the binding to human serum albumin and human plasma has been studied. Piroxicam 20-29 albumin Homo sapiens 114-127 3486075-0 1986 Reduced in vivo leucocyte migration and elastase and lysozyme concentrations in skin chamber experiments with piroxicam in healthy volunteers. Piroxicam 110-119 lysozyme Homo sapiens 53-61 3486075-6 1986 The concentrations of elastase and lysozyme in the skin chamber decreased after six days" medication with piroxicam. Piroxicam 106-115 lysozyme Homo sapiens 35-43 3079606-5 1986 Inhibitors of the CO pathway (indomethacin, piroxicam, and ibuprofen) caused a dose-dependent augmentation in the LPS-induced IL 1 response. Piroxicam 44-53 interleukin 1 complex Mus musculus 126-130 6088878-11 1984 Indomethacin (10(-5) M), piroxicam (10(-6) M), and aspirin, cyclooxygenase antagonists, negated LTB4-, C5a des arg-, and FMLP-induced LAI. Piroxicam 25-34 complement C5a receptor 1 Homo sapiens 103-106 6088878-11 1984 Indomethacin (10(-5) M), piroxicam (10(-6) M), and aspirin, cyclooxygenase antagonists, negated LTB4-, C5a des arg-, and FMLP-induced LAI. Piroxicam 25-34 formyl peptide receptor 1 Homo sapiens 121-125 6090311-2 1984 Pre-incubation of PMNs in vitro with the cyclo-oxygenase (COx) inhibitor piroxicam (50 microM) before stimulation with the chemotactic peptide f-met-leu-phe (FMLP, 10(-7)M) inhibited all of these responses. Piroxicam 73-82 formyl peptide receptor 1 Homo sapiens 158-162 6090311-4 1984 Binding of 3H-FMLP was inhibited by piroxicam. Piroxicam 36-45 formyl peptide receptor 1 Homo sapiens 14-18 6237051-4 1984 A double-blind placebo-controlled study was performed in 20 patients suffering from active RA to investigate the acute effect of a single administration of piroxicam 40 mg on the number of circulating OKT3, T4, T8 and IA1 positive cells. Piroxicam 156-165 insulinoma-associated 1 Mus musculus 218-221 6090311-8 1984 Piroxicam inhibited FMLP-induced aggregation by 31% (5.2 cm2/min versus 3.6 cm2/min, P less than 0.004) and O2- generation by 35% (15.8 nmol cytochrome c reduced versus 10.2 nmol, P less than 0.002). Piroxicam 0-9 formyl peptide receptor 1 Homo sapiens 20-24 6237051-8 1984 The number of IA1 positive cells (B-cells and activated T-lymphocytes) was significantly higher in the afternoon samples (at 14.00 and 16.00 hours) than in the morning samples (at 08.00 and 10.00 hours) after both placebo and piroxicam administration (P less than 0.05). Piroxicam 226-235 insulinoma-associated 1 Mus musculus 14-17 6090311-8 1984 Piroxicam inhibited FMLP-induced aggregation by 31% (5.2 cm2/min versus 3.6 cm2/min, P less than 0.004) and O2- generation by 35% (15.8 nmol cytochrome c reduced versus 10.2 nmol, P less than 0.002). Piroxicam 0-9 cytochrome c, somatic Homo sapiens 141-153 6611436-2 1984 Preincubation of rabbit or human PMN with piroxicam inhibited the cellular responses elicited by N-formyl-methionyl-leucyl-phenylalanine (FMLP) such as superoxide anion (O2-) generation, granule enzyme release and chemotaxis. Piroxicam 42-51 formyl peptide receptor 1 Homo sapiens 138-142 6332779-6 1984 Thus piroxicam and indomethacin prevented the inhibition by endogenous monocyte-derived PGE2 of IL-2 secretion and activity. Piroxicam 5-14 interleukin 2 Homo sapiens 96-100 6611436-5 1984 The inhibitory effect of piroxicam on FMLP-induced O2- generation was dependent on the concentration of stimuli and was reversed by increasing the extracellular calcium concentration. Piroxicam 25-34 formyl peptide receptor 1 Homo sapiens 38-42 6143813-1 1984 Modifications in prolactin specific binding in the rat liver induced by different non-steroidal anti-inflammatory drugs (indomethacin, piroxicam, ketoprofen, phenylbutazone, mefenamic acid and acetylsalicylic acid) have been studied. Piroxicam 135-144 prolactin Rattus norvegicus 17-26 6609435-0 1984 Bleeding tendency possibly related to increased plasma antithrombin III activity in patient treated with piroxicam. Piroxicam 105-114 serpin family C member 1 Homo sapiens 55-71 6442285-2 1984 The most sensitive enzyme was ornithine decarboxylase, for which piroxicam, benoxaprofen and aminophenazone showed an IC50 of 0.007 mM; ibuprofen competitively inhibits the lysine decarboxylase. Piroxicam 65-74 ornithine decarboxylase 1 Rattus norvegicus 30-53 33617802-6 2021 These data indicate that the inhibition effects of Nav1.5 and Kv11.1 by meloxicam, nimesulide, piroxicam, and diclofenac might contribute to their potential cardiac risk. Piroxicam 95-104 sodium voltage-gated channel alpha subunit 5 Homo sapiens 51-57 33617802-6 2021 These data indicate that the inhibition effects of Nav1.5 and Kv11.1 by meloxicam, nimesulide, piroxicam, and diclofenac might contribute to their potential cardiac risk. Piroxicam 95-104 potassium voltage-gated channel subfamily A member 1 Homo sapiens 62-66 31534535-9 2019 Inflammation was observed on H&E staining in IL-10-/- mice with piroxicam promotion, while stable overexpression of P-selectin was not found on immunofluorescence staining in the same mice. Piroxicam 64-73 interleukin 10 Mus musculus 45-50 32162074-11 2020 It was also found that the plant extracts and piroxicam increased (p < 0.05) the activities of superoxide dismutase and catalase in the liver tissue while reduced the level of malondialdehyde in arthritic rats. Piroxicam 46-55 catalase Rattus norvegicus 120-128 31999404-6 2020 The authors examined visceral pain in the IL-10-piroxicam model of chronic colitis, which differs from other experimental IBD models in that it involves immune suppression. Piroxicam 48-57 interleukin 10 Mus musculus 42-47 31809855-4 2020 In this work, the SERS spectra of piroxicam polymorphic forms beta and alpha2 are presented. Piroxicam 34-43 seryl-tRNA synthetase 2, mitochondrial Homo sapiens 18-22 32570035-7 2020 Further, mouse models with dextran sulfate sodium-induced acute colitis and piroxicam-induced IL-10-/- chronic colitis were generated. Piroxicam 76-85 interleukin 10 Mus musculus 94-99 32141013-11 2020 Gene expression level of TNF-alpha, IL-6 and IL-1beta was significantly reduced by amlodipine while an increase in expression level of IL-4 and IL-10 was evident in animals treated with piroxicam and amlodipine. Piroxicam 186-195 tumor necrosis factor Homo sapiens 25-34 32141013-11 2020 Gene expression level of TNF-alpha, IL-6 and IL-1beta was significantly reduced by amlodipine while an increase in expression level of IL-4 and IL-10 was evident in animals treated with piroxicam and amlodipine. Piroxicam 186-195 interleukin 4 Homo sapiens 135-139 32141013-11 2020 Gene expression level of TNF-alpha, IL-6 and IL-1beta was significantly reduced by amlodipine while an increase in expression level of IL-4 and IL-10 was evident in animals treated with piroxicam and amlodipine. Piroxicam 186-195 interleukin 10 Homo sapiens 144-149 32575617-5 2020 The interaction between piroxicam and a beta-CD nanosponge (NS) was then modeled at different concentrations. Piroxicam 24-33 ACD shelterin complex subunit and telomerase recruitment factor Homo sapiens 40-47 32525927-0 2020 Retraction: Aquaporin-4 Inhibition Mediates Piroxicam-Induced Neuroprotection against Focal Cerebral Ischemia/Reperfusion Injury in Rodents. Piroxicam 44-53 aquaporin 4 Homo sapiens 12-23 31315508-0 2020 Interaction of piroxicam with bovine serum albumin investigated by spectroscopic, calorimetric and computational molecular methods. Piroxicam 15-24 albumin Homo sapiens 37-50 31315508-2 2020 In this study, the nature and magnitude of the interactions between piroxicam (PRX) and bovine serum albumin (BSA) was assessed using spectroscopic, calorimetric and computational molecular methods. Piroxicam 68-77 albumin Homo sapiens 95-114 31678245-8 2019 In conclusion, our data support the role of piroxicam and sulindac sulfide in suppressing inflammation-driven breast cancer progression and identifies promising novel target in RAS and PAR-4 signaling. Piroxicam 44-53 Prader Willi/Angelman region RNA 4 Homo sapiens 185-190 30339576-11 2019 The incidence of new-onset breast cancer in NSAID users was significantly decreased in users taking selective cyclooxygenase 2 inhibitors, diclofenac, ibuprofen and piroxicam. Piroxicam 165-174 prostaglandin-endoperoxide synthase 2 Homo sapiens 110-126 31108878-8 2019 3D-RISM calculations on piroxicam-bound DPP-4 were used to understand the stability of water molecules at the active site. Piroxicam 24-33 dipeptidyl peptidase 4 Homo sapiens 40-45 31184596-5 2019 The apolipoprotein A-I (APOA1) mimetic 4F mitigated disease in both the Cox2 MKO/CCHF and piroxicam-accelerated Il10-/- models of inflammatory bowel disease (IBD) and reduced elevated levels of pro-inflammatory mediators in tissue and plasma. Piroxicam 90-99 apolipoprotein A-I Mus musculus 4-22 31184596-5 2019 The apolipoprotein A-I (APOA1) mimetic 4F mitigated disease in both the Cox2 MKO/CCHF and piroxicam-accelerated Il10-/- models of inflammatory bowel disease (IBD) and reduced elevated levels of pro-inflammatory mediators in tissue and plasma. Piroxicam 90-99 apolipoprotein A-I Mus musculus 24-29 31184596-5 2019 The apolipoprotein A-I (APOA1) mimetic 4F mitigated disease in both the Cox2 MKO/CCHF and piroxicam-accelerated Il10-/- models of inflammatory bowel disease (IBD) and reduced elevated levels of pro-inflammatory mediators in tissue and plasma. Piroxicam 90-99 interleukin 10 Mus musculus 112-116 31108878-9 2019 Finally, piroxicam was chosen as the repurposing drug to become a new DPP-4 inhibitor and validated experimentally using fluorescence spectroscopy assay. Piroxicam 9-18 dipeptidyl peptidase 4 Homo sapiens 70-75 31108878-10 2019 These findings are novel and provide new insights into the role of piroxicam as a new lead to inhibit DPP-4 and, taking into consideration the biological half-life of piroxicam, it can be proposed as a possible therapeutic strategy for treating diabetes mellitus. Piroxicam 67-76 dipeptidyl peptidase 4 Homo sapiens 102-107 29994939-3 2018 The recent pharmacogenetics studies revealed an association of the organic cation transporter 1 (OCT1) and ATP-binding cassette C3 (ABCC3) polymorphisms with morphine-related adverse effects, an effect of polymorphisms in cytochrome P450 gene CYP2D6 on the analgesic efficacy of tramadol and no effect of CYP2C8 and CYP2C9 variants on efficacy of piroxicam. Piroxicam 347-356 solute carrier family 22 member 1 Homo sapiens 67-95 30005203-6 2018 The moderate selective COX-2 inhibitor; dimethoxychalcone 11d (SI = 103) displayed excellent anti-inflammatory activity (% edema inhibition = 45.8-59.3) and increased thermal pain threshold (50-92.85%) comparable to piroxicam (75%). Piroxicam 216-225 mitochondrially encoded cytochrome c oxidase II Homo sapiens 23-28 29994939-3 2018 The recent pharmacogenetics studies revealed an association of the organic cation transporter 1 (OCT1) and ATP-binding cassette C3 (ABCC3) polymorphisms with morphine-related adverse effects, an effect of polymorphisms in cytochrome P450 gene CYP2D6 on the analgesic efficacy of tramadol and no effect of CYP2C8 and CYP2C9 variants on efficacy of piroxicam. Piroxicam 347-356 solute carrier family 22 member 1 Homo sapiens 97-101 29994939-3 2018 The recent pharmacogenetics studies revealed an association of the organic cation transporter 1 (OCT1) and ATP-binding cassette C3 (ABCC3) polymorphisms with morphine-related adverse effects, an effect of polymorphisms in cytochrome P450 gene CYP2D6 on the analgesic efficacy of tramadol and no effect of CYP2C8 and CYP2C9 variants on efficacy of piroxicam. Piroxicam 347-356 ATP binding cassette subfamily C member 3 Homo sapiens 132-137 28034279-9 2017 Inhibition of acetylcholinesterase activity was also potent and was in the following order: celecoxib> piroxicam> diclofenac> aspirin> indomethacin> dexamethasone. Piroxicam 106-115 acetylcholinesterase (Cartwright blood group) Homo sapiens 14-34 30192835-8 2018 Inhibition of COX with piroxicam, therefore reduction of prostaglandin formation in the chronically inflamed intestine, reversed the inhibition of B0AT1 to its normal levels. Piroxicam 23-32 solute carrier family 6 member 19 Homo sapiens 147-152 29582369-9 2018 Reported results have been similar for another non-steroidal anti-inflammatory drug (NSAID), piroxicam, which has more cyclooxygenase (COX)-1 activity than DFS. Piroxicam 93-102 mitochondrially encoded cytochrome c oxidase I Homo sapiens 119-141 29216591-8 2018 alpha-Lactalbumin was released faster from the PLGA-1-methyl-2-pyrrolidinone system than the PLGA-triacetin system opposite to the piroxicam release pattern. Piroxicam 131-140 lactalbumin alpha Homo sapiens 0-17 28957780-8 2017 Etoposide single agent treatment and combination treatment with piroxicam down-regulated survivin expression, but was not followed by increased apoptotic activity. Piroxicam 64-73 baculoviral IAP repeat containing 5 Canis lupus familiaris 89-97 28740425-0 2017 Efficacy of piroxicam for postoperative pain after lower third molar surgery associated with CYP2C8*3 and CYP2C9. Piroxicam 12-21 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 93-99 28740425-0 2017 Efficacy of piroxicam for postoperative pain after lower third molar surgery associated with CYP2C8*3 and CYP2C9. Piroxicam 12-21 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 106-112 28740425-2 2017 The aim of this study was to evaluate the possible association of polymorphisms in the CYP2C8*3 and CYP2C9 genes with the clinical efficacy of oral piroxicam (20 mg daily for 4 days) after lower third molar surgeries with regard to postoperative pain, swelling, trismus, adverse reactions, need for rescue medication and the volunteer"s overall satisfaction. Piroxicam 148-157 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 87-93 28740425-2 2017 The aim of this study was to evaluate the possible association of polymorphisms in the CYP2C8*3 and CYP2C9 genes with the clinical efficacy of oral piroxicam (20 mg daily for 4 days) after lower third molar surgeries with regard to postoperative pain, swelling, trismus, adverse reactions, need for rescue medication and the volunteer"s overall satisfaction. Piroxicam 148-157 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 100-106 27016022-7 2016 Treatment with ibuprofen or piroxicam in combination with l-dopa preserved the effect of l-dopa at the end of week 10, delayed the development of dyskinesia and decreased striatal COX-2 and VEGF levels. Piroxicam 28-37 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 180-185 27016022-7 2016 Treatment with ibuprofen or piroxicam in combination with l-dopa preserved the effect of l-dopa at the end of week 10, delayed the development of dyskinesia and decreased striatal COX-2 and VEGF levels. Piroxicam 28-37 vascular endothelial growth factor A Rattus norvegicus 190-194 26481545-0 2015 Piroxicam, a traditional non-steroidal anti-inflammatory drug (NSAID) causes apoptosis by ROS mediated Akt activation. Piroxicam 0-9 AKT serine/threonine kinase 1 Homo sapiens 103-106 26481545-10 2015 Thus we revealed for the first time that Px can induce apoptosis by ROS mediated Akt hyperphosphorylation/activation. Piroxicam 41-43 AKT serine/threonine kinase 1 Homo sapiens 81-84 25939041-10 2015 Bone marrow cells from IL-10(-/-) mice were sufficient to restore protection against the heightened colitis in piroxicam-fed DKO mice. Piroxicam 111-120 interleukin 10 Mus musculus 23-28 26408892-4 2015 Response was linear function of concentration over the ranges of 70-130 mg mL-1 for piroxicam and ofloxacin (r2 >= 0.999). Piroxicam 84-93 L1 cell adhesion molecule Mus musculus 75-79 25939041-8 2015 RESULTS: C3a and C5a levels and C9 deposition were all increased in piroxicam-fed IL-10(-/-) mice compared with mice not fed piroxicam. Piroxicam 68-77 interleukin 10 Mus musculus 82-87 25569742-0 2015 Piroxicam treatment augments bone abnormalities in interleukin-10 knockout mice. Piroxicam 0-9 interleukin 10 Mus musculus 51-65 25459509-1 2015 A new mononuclear Zn(II) complex, trans-[Zn(Pir)2(DMSO)2], where Pir(-) is 4-hydroxy-2-methyl-N-2-pyridyl-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide (piroxicam), has been synthesized and characterized. Piroxicam 75-152 ring finger protein 144B Homo sapiens 44-49 25522350-5 2015 Piroxicam and niflumic acid inhibited UGT1A9 activity (IC50 = 73.8 mum and 0.38 mum, respectively) and naproxen selectively inhibited UGT2B7 activity (IC50 = 53.1 mum), whereas it did not inhibit the other UGTs tested (IC50 > 200 mum). Piroxicam 0-9 UDP glucuronosyltransferase family 1 member A9 Homo sapiens 38-44 26124563-0 2015 Piroxicam confer neuroprotection in Cerebral Ischemia by inhibiting Cyclooxygenases, Acid- Sensing Ion Channel-1a and Aquaporin-4: an in silico comparison with Aspirin and Nimesulide. Piroxicam 0-9 aquaporin 4 Homo sapiens 118-129 25092068-8 2015 Delivered cisplatin cooperated with piroxicam in modulating cell cycle regulators as caspase-3, p53 and p21. Piroxicam 36-45 caspase 3 Homo sapiens 85-94 25092068-8 2015 Delivered cisplatin cooperated with piroxicam in modulating cell cycle regulators as caspase-3, p53 and p21. Piroxicam 36-45 tumor protein p53 Homo sapiens 96-99 25092068-8 2015 Delivered cisplatin cooperated with piroxicam in modulating cell cycle regulators as caspase-3, p53 and p21. Piroxicam 36-45 H3 histone pseudogene 16 Homo sapiens 104-107 25825916-7 2015 Piroxicam and c-phycocyanin also stimulated antiproliferation by restraining PCNA expression and reduced cell survival via inhibiting NFkappaB (p65) pathway. Piroxicam 0-9 proliferating cell nuclear antigen Rattus norvegicus 77-81 24725029-12 2015 ME1 showed significantly higher anti-inflammatory activity versus the standard TD anti-inflammatory piroxicam. Piroxicam 100-109 malic enzyme 1 Homo sapiens 0-3 25825916-7 2015 Piroxicam and c-phycocyanin also stimulated antiproliferation by restraining PCNA expression and reduced cell survival via inhibiting NFkappaB (p65) pathway. Piroxicam 0-9 synaptotagmin 1 Rattus norvegicus 144-147 25825916-9 2015 Inhibition of cyclin/CDK complex by piroxicam and c-phycocyanin affects the expression of p53 in colon cancer followed by downregulation of NFkappaB and PCNA levels, thus substantiating the antineoplastic role of these agents. Piroxicam 36-45 proliferating cell nuclear antigen Rattus norvegicus 14-20 25825916-9 2015 Inhibition of cyclin/CDK complex by piroxicam and c-phycocyanin affects the expression of p53 in colon cancer followed by downregulation of NFkappaB and PCNA levels, thus substantiating the antineoplastic role of these agents. Piroxicam 36-45 cyclin dependent kinase 2 Rattus norvegicus 21-24 25825916-9 2015 Inhibition of cyclin/CDK complex by piroxicam and c-phycocyanin affects the expression of p53 in colon cancer followed by downregulation of NFkappaB and PCNA levels, thus substantiating the antineoplastic role of these agents. Piroxicam 36-45 Wistar clone pR53P1 p53 pseudogene Rattus norvegicus 90-93 25825916-9 2015 Inhibition of cyclin/CDK complex by piroxicam and c-phycocyanin affects the expression of p53 in colon cancer followed by downregulation of NFkappaB and PCNA levels, thus substantiating the antineoplastic role of these agents. Piroxicam 36-45 proliferating cell nuclear antigen Rattus norvegicus 153-157 25459137-0 2014 Inhibition of matrix metalloproteinase-2 and 9 by Piroxicam confer neuroprotection in cerebral ischemia: an in silico evaluation of the hypothesis. Piroxicam 50-59 matrix metallopeptidase 2 Mus musculus 14-46 25380501-7 2014 Here we have synthesized and used Cu(II) complexes of fusogenic oxicam NSAIDs, Meloxicam and Piroxicam, to induce fusion in model membranes monitored by using DSC, TEM, steady-state, and time-resolved spectroscopy. Piroxicam 93-102 MFT2 Homo sapiens 164-167 25459137-5 2014 Piroxicam, which is a non-steroidal anti-inflammatory drug (NSAID), has been demonstrated to be protective against aquaporin-4 and acid-sensing ion channel 1a--mediated neurodegeneration in CI. Piroxicam 0-9 aquaporin 4 Mus musculus 115-126 25459137-7 2014 We tested the hypothesis that Piroxicam, with its larger molecular size and more number of interacting pharmacophores, can inhibit MMP-2 and MMP-9. Piroxicam 30-39 matrix metallopeptidase 2 Mus musculus 131-136 25459137-7 2014 We tested the hypothesis that Piroxicam, with its larger molecular size and more number of interacting pharmacophores, can inhibit MMP-2 and MMP-9. Piroxicam 30-39 matrix metallopeptidase 9 Mus musculus 141-146 25459147-0 2014 Piroxicam inhibits NMDA receptor-mediated excitotoxicity through allosteric inhibition of the GluN2B subunit: an in silico study elucidating a novel mechanism of action of the drug. Piroxicam 0-9 glutamate ionotropic receptor NMDA type subunit 2B Homo sapiens 94-100 25459147-7 2014 By using molecular docking as a tool, we validated the hypothesis and hereby report for the first time that Piroxicam can inhibit GluN2B containing NMDARs through allosteric mode similar to the well known selective antagonist--Ifenprodil; and thus can be a therapeutic drug for the prevention of excitotoxic neurodegeneration. Piroxicam 108-117 glutamate ionotropic receptor NMDA type subunit 2B Homo sapiens 130-136 24631063-0 2014 Piroxicam inhibits Masitinib-induced cyclooxygenase 2 expression in oral squamous cell carcinoma cells in vitro. Piroxicam 0-9 prostaglandin-endoperoxide synthase 2 Homo sapiens 37-53 24943733-10 2014 Piroxicam, used as reference drug, significantly reduced the levels of COX-1, COX-2, PGE2, NF-kB, and TNF-alpha, but did not show reduction in 5-LOX and toll-like receptor 2 levels. Piroxicam 0-9 cytochrome c oxidase I, mitochondrial Rattus norvegicus 71-76 24943733-10 2014 Piroxicam, used as reference drug, significantly reduced the levels of COX-1, COX-2, PGE2, NF-kB, and TNF-alpha, but did not show reduction in 5-LOX and toll-like receptor 2 levels. Piroxicam 0-9 cytochrome c oxidase II, mitochondrial Rattus norvegicus 78-83 24943733-10 2014 Piroxicam, used as reference drug, significantly reduced the levels of COX-1, COX-2, PGE2, NF-kB, and TNF-alpha, but did not show reduction in 5-LOX and toll-like receptor 2 levels. Piroxicam 0-9 nuclear factor kappa B subunit 1 Rattus norvegicus 91-96 24943733-10 2014 Piroxicam, used as reference drug, significantly reduced the levels of COX-1, COX-2, PGE2, NF-kB, and TNF-alpha, but did not show reduction in 5-LOX and toll-like receptor 2 levels. Piroxicam 0-9 tumor necrosis factor Rattus norvegicus 102-111 24943733-11 2014 However piroxicam significantly enhanced the levels of IL-4. Piroxicam 8-17 interleukin 4 Rattus norvegicus 55-59 24631063-7 2014 Cotreatment of piroxicam with Masitinib significantly inhibited cell proliferation of OSCC as compared to either drug alone through the c-kit and AKT signaling pathways. Piroxicam 15-24 KIT proto-oncogene, receptor tyrosine kinase Homo sapiens 136-141 24631063-7 2014 Cotreatment of piroxicam with Masitinib significantly inhibited cell proliferation of OSCC as compared to either drug alone through the c-kit and AKT signaling pathways. Piroxicam 15-24 AKT serine/threonine kinase 1 Homo sapiens 146-149 24631063-8 2014 Piroxicam inhibited Masitinib-induced COX-2 expression in all tested OSCCs. Piroxicam 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 38-43 23994255-0 2014 Characterisation of enterocolitis in the piroxicam-accelerated interleukin-10 knock out mouse--a model mimicking inflammatory bowel disease. Piroxicam 41-50 interleukin 10 Mus musculus 63-77 24861078-11 2014 Piroxicam docked in VEGF-A binding site of VEGF-A receptors i.e., VEGFR1 and VEGFR2, while phycocyanobilin (a chromophore of C-phycocyanin) docked with VEGFR1 alone. Piroxicam 0-9 vascular endothelial growth factor A Rattus norvegicus 20-26 24861078-11 2014 Piroxicam docked in VEGF-A binding site of VEGF-A receptors i.e., VEGFR1 and VEGFR2, while phycocyanobilin (a chromophore of C-phycocyanin) docked with VEGFR1 alone. Piroxicam 0-9 vascular endothelial growth factor A Rattus norvegicus 43-49 24861078-11 2014 Piroxicam docked in VEGF-A binding site of VEGF-A receptors i.e., VEGFR1 and VEGFR2, while phycocyanobilin (a chromophore of C-phycocyanin) docked with VEGFR1 alone. Piroxicam 0-9 Fms related receptor tyrosine kinase 1 Rattus norvegicus 66-72 24861078-11 2014 Piroxicam docked in VEGF-A binding site of VEGF-A receptors i.e., VEGFR1 and VEGFR2, while phycocyanobilin (a chromophore of C-phycocyanin) docked with VEGFR1 alone. Piroxicam 0-9 kinase insert domain receptor Rattus norvegicus 77-83 24861078-11 2014 Piroxicam docked in VEGF-A binding site of VEGF-A receptors i.e., VEGFR1 and VEGFR2, while phycocyanobilin (a chromophore of C-phycocyanin) docked with VEGFR1 alone. Piroxicam 0-9 Fms related receptor tyrosine kinase 1 Rattus norvegicus 152-158 24797915-0 2014 Predictive validity and immune cell involvement in the pathogenesis of piroxicam-accelerated colitis in interleukin-10 knockout mice. Piroxicam 71-80 interleukin 10 Mus musculus 104-118 24797915-1 2014 Piroxicam administration is a method for induction of enterocolitis in interleukin-10 knockout (IL-10 k.o.) Piroxicam 0-9 interleukin 10 Mus musculus 71-85 24797915-1 2014 Piroxicam administration is a method for induction of enterocolitis in interleukin-10 knockout (IL-10 k.o.) Piroxicam 0-9 interleukin 10 Mus musculus 96-101 24721324-0 2014 Piroxicam and c-phycocyanin prevent colon carcinogenesis by inhibition of membrane fluidity and canonical Wnt/beta-catenin signaling while up-regulating ligand dependent transcription factor PPARgamma. Piroxicam 0-9 Wnt family member 2 Rattus norvegicus 106-109 24721324-0 2014 Piroxicam and c-phycocyanin prevent colon carcinogenesis by inhibition of membrane fluidity and canonical Wnt/beta-catenin signaling while up-regulating ligand dependent transcription factor PPARgamma. Piroxicam 0-9 catenin beta 1 Rattus norvegicus 110-122 24721324-0 2014 Piroxicam and c-phycocyanin prevent colon carcinogenesis by inhibition of membrane fluidity and canonical Wnt/beta-catenin signaling while up-regulating ligand dependent transcription factor PPARgamma. Piroxicam 0-9 peroxisome proliferator-activated receptor gamma Rattus norvegicus 191-200 24721324-9 2014 We conclude that piroxicam and c-phycocyanin exert their anti-neoplastic effects via regulating membrane properties, raising calpain-9 and PPARgamma expression while suppressing Wnt/beta-catenin signaling in experimental colon carcinogenesis. Piroxicam 17-26 calpain 9 Rattus norvegicus 125-134 24721324-9 2014 We conclude that piroxicam and c-phycocyanin exert their anti-neoplastic effects via regulating membrane properties, raising calpain-9 and PPARgamma expression while suppressing Wnt/beta-catenin signaling in experimental colon carcinogenesis. Piroxicam 17-26 peroxisome proliferator-activated receptor gamma Rattus norvegicus 139-148 24721324-9 2014 We conclude that piroxicam and c-phycocyanin exert their anti-neoplastic effects via regulating membrane properties, raising calpain-9 and PPARgamma expression while suppressing Wnt/beta-catenin signaling in experimental colon carcinogenesis. Piroxicam 17-26 Wnt family member 2 Rattus norvegicus 178-181 24721324-9 2014 We conclude that piroxicam and c-phycocyanin exert their anti-neoplastic effects via regulating membrane properties, raising calpain-9 and PPARgamma expression while suppressing Wnt/beta-catenin signaling in experimental colon carcinogenesis. Piroxicam 17-26 catenin beta 1 Rattus norvegicus 182-194 24170253-2 2014 Mucosa-free longitudinal smooth muscle strips of the rat middle colon spontaneously induced frequent phasic contractions (giant contractions, GCs) in vitro, and the GCs were almost completely abolished by a cyclooxygenase inhibitor, piroxicam, and by an EP3 receptor antagonist, ONO-AE3-240, but enhanced by tetrodotoxin (TTX). Piroxicam 233-242 prostaglandin E receptor 3 Rattus norvegicus 254-257 24170253-3 2014 In the presence of piroxicam, exogenous PGE2, both ONO-AE-248 (EP3 agonist), and ONO-DI-004 (EP1 agonist) induced GC-like contractions, and increased the frequency and amplitude. Piroxicam 19-28 prostaglandin E receptor 3 Rattus norvegicus 63-66 24170253-3 2014 In the presence of piroxicam, exogenous PGE2, both ONO-AE-248 (EP3 agonist), and ONO-DI-004 (EP1 agonist) induced GC-like contractions, and increased the frequency and amplitude. Piroxicam 19-28 prostaglandin E receptor 1 Rattus norvegicus 93-96 23994255-2 2014 Piroxicam treatment is a method for induction of colitis in IL-10 k.o. Piroxicam 0-9 interleukin 10 Mus musculus 60-65 23994255-5 2014 AIM: To characterise the piroxicam-accelerated colitis (PAC) IL-10 k.o. Piroxicam 25-34 interleukin 10 Mus musculus 61-66 24023878-0 2013 Aquaporin-4 inhibition mediates piroxicam-induced neuroprotection against focal cerebral ischemia/reperfusion injury in rodents. Piroxicam 32-41 aquaporin 4 Rattus norvegicus 0-11 23933501-7 2013 UII was also found to induce prostacyclin (PGI2) production, which caused peroxisomal proliferator-activated receptor alpha (PPARalpha) activation as revealed by both PGI2 synthase siRNA transfection and piroxicam treatment. Piroxicam 204-213 urotensin 2 Rattus norvegicus 0-3 23949641-4 2013 METHODS: Colitis was induced by giving 10-week old IL-10-/- mice piroxicam (P.O.) Piroxicam 65-74 interleukin 10 Mus musculus 51-56 23904182-1 2013 The purpose of this study was to formulate printable dosage forms for a poorly soluble drug (piroxicam; PRX) and to gain understanding of critical parameters to be considered during development of such dosage forms. Piroxicam 93-102 periaxin Homo sapiens 104-107 24023878-4 2013 We have found that Piroxicam binds to AQP4 with optimal binding energy value. Piroxicam 19-28 aquaporin 4 Rattus norvegicus 38-42 24023878-5 2013 Thus, we hypothesized that Piroxicam is neuroprotective in the rodent cerebral ischemic model by mitigating cerebral edema via AQP4 regulation. Piroxicam 27-36 aquaporin 4 Rattus norvegicus 127-131 24023878-12 2013 CONCLUSIONS: Findings of the present study provide significant evidence that Piroxicam acts as a potent AQP4 regulator and renders neuroprotection in focal cerebral ischemia. Piroxicam 77-86 aquaporin 4 Rattus norvegicus 104-108 23514809-6 2013 Increased apoptotic index and stimulated levels of Bcl-2-associated death promoter (Bad), a proapoptotic protein, were observed in piroxicam-treated and c-phycocyanin-treated rats. Piroxicam 131-140 BCL2-associated agonist of cell death Rattus norvegicus 51-82 23801651-3 2013 In this study, we investigated whether DHNA attenuates inflammation in piroxicam-treated IL-10(-/-) mice, particularly focusing on the changes of the host immune mechanism. Piroxicam 71-80 interleukin 10 Mus musculus 89-94 23801651-9 2013 Taken together, these findings suggest that administration of DHNA is useful for the treatment of colitis in piroxicam-treated IL-10(-/-) mice and that attenuation of colitis by DHNA may partly be a result of its direct action on intestinal macrophages to inhibit proinflammatory cytokine production. Piroxicam 109-118 interleukin 10 Mus musculus 127-132 23487439-11 2013 The PI3K/AKT pathway is essential for tumor invasion and the malignant features of the piroxicam/IL-10(-/-) mouse model. Piroxicam 87-96 thymoma viral proto-oncogene 1 Mus musculus 9-12 23514809-7 2013 In-silico molecular docking of piroxicam as a ligand with several regulatory proteins was performed, indicating that, except inducible nitric oxide synthase, it effectively binds with COX-1, COX-2, Jak3, and Stat3. Piroxicam 31-40 cytochrome c oxidase II, mitochondrial Rattus norvegicus 191-196 23514809-7 2013 In-silico molecular docking of piroxicam as a ligand with several regulatory proteins was performed, indicating that, except inducible nitric oxide synthase, it effectively binds with COX-1, COX-2, Jak3, and Stat3. Piroxicam 31-40 Janus kinase 3 Rattus norvegicus 198-202 23514809-7 2013 In-silico molecular docking of piroxicam as a ligand with several regulatory proteins was performed, indicating that, except inducible nitric oxide synthase, it effectively binds with COX-1, COX-2, Jak3, and Stat3. Piroxicam 31-40 signal transducer and activator of transcription 3 Rattus norvegicus 208-213 23514809-8 2013 Piroxicam and c-phycocyanin perhaps showed chemopreventive properties by inhibiting proinflammatory cytokines and Jak3/Stat3 signaling while promoting apoptosis. Piroxicam 0-9 Janus kinase 3 Rattus norvegicus 114-118 23514809-8 2013 Piroxicam and c-phycocyanin perhaps showed chemopreventive properties by inhibiting proinflammatory cytokines and Jak3/Stat3 signaling while promoting apoptosis. Piroxicam 0-9 signal transducer and activator of transcription 3 Rattus norvegicus 119-124 23179355-4 2013 Treatment with the non-selective cyclooxygenase (COX) inhibitor ketoprofen and the COX-2 selective inhibitor nimesulide attenuated the increase in extracellular glutamate in the hippocampus evoked by repeated MDMA exposure (10 mg/kg, i.p., every 2 h); no attenuation was observed in rats treated with the COX-1 selective inhibitor piroxicam. Piroxicam 331-340 cytochrome c oxidase II, mitochondrial Rattus norvegicus 83-88 22874452-3 2012 In this context, we hypothesize the combination effect of Piroxicam, a Non steroidal anti inflammatory drug with Ifenprodil, a NR2b selective NMDAR antagonist in animal model of cerebral ischemia. Piroxicam 58-67 glutamate ionotropic receptor NMDA type subunit 2B Homo sapiens 127-131 23569374-5 2013 In addition, the liposomal piroxicam formulation resulted in statistically stronger inhibition of pro-inflammatory mediators (ie, nitric oxide, tumor necrosis factor-alpha, interleukin-1beta, and prostaglandin E2) than piroxicam at an equivalent dose. Piroxicam 27-36 tumor necrosis factor Mus musculus 144-171 23569374-5 2013 In addition, the liposomal piroxicam formulation resulted in statistically stronger inhibition of pro-inflammatory mediators (ie, nitric oxide, tumor necrosis factor-alpha, interleukin-1beta, and prostaglandin E2) than piroxicam at an equivalent dose. Piroxicam 27-36 interleukin 1 beta Mus musculus 173-190 23569374-6 2013 The liposome-encapsulated piroxicam also caused statistically significant production of interleukin-10, an anti-inflammatory cytokine. Piroxicam 26-35 interleukin 10 Mus musculus 88-102 22795752-0 2012 Neuroprotective potential of Piroxicam in cerebral ischemia: an in silico evaluation of the hypothesis to explore its therapeutic efficacy by inhibition of aquaporin-4 and acid sensing ion channel1a. Piroxicam 29-38 aquaporin 4 Homo sapiens 156-167 22795752-7 2012 Therefore, the target of the present in silico study was to determine the neuroprotective efficacy of Piroxicam, a NSAID in animal model of cerebral ischemia/reperfusion (I/R) injury and efforts were made to analyze its inhibitory effects on aquaporin-4 activation and ASIC1a channels mediated downstream survival/damage mechanisms. Piroxicam 102-111 aquaporin 4 Homo sapiens 242-253 22795752-8 2012 Thus we hypothesized that Piroxicam, a NSAID can act as a neuroprotective agent in animal model of cerebral ischemia/reperfusion (I/R) injury due to its inhibitory effects on aquaporin-4 channel and ASIC1a channels. Piroxicam 26-35 aquaporin 4 Homo sapiens 175-186 22561258-8 2012 The present study thus identified that piroxicam, a traditional NSAID and c-phycocyanin, a newly discovered COX-2 selective inhibitor, constitute remarkable chemopreventive targets in mediating apoptosis in the DMH induced early rat colon carcinogenesis via regulating PI3-K/Akt/GSK-3beta/PTEN signaling pathways. Piroxicam 39-48 AKT serine/threonine kinase 1 Rattus norvegicus 275-278 22561258-8 2012 The present study thus identified that piroxicam, a traditional NSAID and c-phycocyanin, a newly discovered COX-2 selective inhibitor, constitute remarkable chemopreventive targets in mediating apoptosis in the DMH induced early rat colon carcinogenesis via regulating PI3-K/Akt/GSK-3beta/PTEN signaling pathways. Piroxicam 39-48 glycogen synthase kinase 3 beta Rattus norvegicus 279-288 22561258-6 2012 Piroxicam and c-phycocyanin treatment resulted significant apoptotic cell death while showing low PI3-K and Akt expressions. Piroxicam 0-9 AKT serine/threonine kinase 1 Rattus norvegicus 108-111 22561258-8 2012 The present study thus identified that piroxicam, a traditional NSAID and c-phycocyanin, a newly discovered COX-2 selective inhibitor, constitute remarkable chemopreventive targets in mediating apoptosis in the DMH induced early rat colon carcinogenesis via regulating PI3-K/Akt/GSK-3beta/PTEN signaling pathways. Piroxicam 39-48 phosphatase and tensin homolog Rattus norvegicus 289-293 22369161-6 2012 Results illustrated that piroxicam and c-phycocyanin treatments stimulate cytochrome c release by downregulating the Bcl-2 (an antiapoptotic protein) expression significantly, while promoting the level of Bax (a proapoptotic protein), thereby activating caspases (caspases-9 and -3) and Apaf-1. Piroxicam 25-34 BCL2, apoptosis regulator Rattus norvegicus 117-122 22369161-6 2012 Results illustrated that piroxicam and c-phycocyanin treatments stimulate cytochrome c release by downregulating the Bcl-2 (an antiapoptotic protein) expression significantly, while promoting the level of Bax (a proapoptotic protein), thereby activating caspases (caspases-9 and -3) and Apaf-1. Piroxicam 25-34 caspase 9 Rattus norvegicus 264-281 22369161-6 2012 Results illustrated that piroxicam and c-phycocyanin treatments stimulate cytochrome c release by downregulating the Bcl-2 (an antiapoptotic protein) expression significantly, while promoting the level of Bax (a proapoptotic protein), thereby activating caspases (caspases-9 and -3) and Apaf-1. Piroxicam 25-34 BCL2 associated X, apoptosis regulator Rattus norvegicus 205-208 22369161-6 2012 Results illustrated that piroxicam and c-phycocyanin treatments stimulate cytochrome c release by downregulating the Bcl-2 (an antiapoptotic protein) expression significantly, while promoting the level of Bax (a proapoptotic protein), thereby activating caspases (caspases-9 and -3) and Apaf-1. Piroxicam 25-34 apoptotic peptidase activating factor 1 Rattus norvegicus 287-293 22369161-6 2012 Results illustrated that piroxicam and c-phycocyanin treatments stimulate cytochrome c release by downregulating the Bcl-2 (an antiapoptotic protein) expression significantly, while promoting the level of Bax (a proapoptotic protein), thereby activating caspases (caspases-9 and -3) and Apaf-1. Piroxicam 25-34 caspase 9 Rattus norvegicus 254-262 22208783-11 2011 Early decreases in IL-6 serum levels with piroxicam correlated with better muscle performance at week 2. Piroxicam 42-51 interleukin 6 Homo sapiens 19-23 22182582-6 2012 Tenoxicam and piroxicam prevented MPP(+)-induced reduction of phosphorylated Akt levels in cells: a protective mechanism similar to that of meloxicam. Piroxicam 14-23 AKT serine/threonine kinase 1 Homo sapiens 77-80 22057579-12 2012 Serum Hsp70 levels decreased significantly in the piroxicam group, but not in the placebo group. Piroxicam 50-59 heat shock protein family A (Hsp70) member 4 Homo sapiens 6-11 22057579-13 2012 Without heat challenge, intracellular levels of Hsp70 in monocytes decreased in both groups, whereas HsP27 in monocytes increased with piroxicam with a significant difference compared to placebo at 3 weeks. Piroxicam 135-144 heat shock protein family B (small) member 1 Homo sapiens 101-106 22208783-12 2011 Basal expression of Hsp27 in monocytes without heat challenge (WHC) was positively correlated with FR at baseline and significantly increased by treatment with piroxicam compared to placebo. Piroxicam 160-169 heat shock protein family B (small) member 1 Homo sapiens 20-25 21463481-4 2011 The aim of this study was to investigate the effects of piroxicam, a preferential COX-1 inhibitor, on the endotoxin-induced changes in blood pressure, expression of COX-1, inducible COX (COX-2), CYP4A1, eNOS, iNOS and heat shock protein 90 (hsp90), and production of PGI(2), PGE(2), 20-HETE and NO. Piroxicam 56-65 cytochrome c oxidase I, mitochondrial Rattus norvegicus 82-87 21463481-4 2011 The aim of this study was to investigate the effects of piroxicam, a preferential COX-1 inhibitor, on the endotoxin-induced changes in blood pressure, expression of COX-1, inducible COX (COX-2), CYP4A1, eNOS, iNOS and heat shock protein 90 (hsp90), and production of PGI(2), PGE(2), 20-HETE and NO. Piroxicam 56-65 cytochrome c oxidase I, mitochondrial Rattus norvegicus 165-170 21463481-9 2011 The effects of endotoxin, except for renal COX-1 and eNOS protein expression, were prevented by piroxicam (10 mg/kg, i.p. Piroxicam 96-105 cytochrome c oxidase I, mitochondrial Rattus norvegicus 43-48 21463481-4 2011 The aim of this study was to investigate the effects of piroxicam, a preferential COX-1 inhibitor, on the endotoxin-induced changes in blood pressure, expression of COX-1, inducible COX (COX-2), CYP4A1, eNOS, iNOS and heat shock protein 90 (hsp90), and production of PGI(2), PGE(2), 20-HETE and NO. Piroxicam 56-65 cytochrome c oxidase II, mitochondrial Rattus norvegicus 82-85 21463481-9 2011 The effects of endotoxin, except for renal COX-1 and eNOS protein expression, were prevented by piroxicam (10 mg/kg, i.p. Piroxicam 96-105 nitric oxide synthase 3 Rattus norvegicus 53-57 21463481-4 2011 The aim of this study was to investigate the effects of piroxicam, a preferential COX-1 inhibitor, on the endotoxin-induced changes in blood pressure, expression of COX-1, inducible COX (COX-2), CYP4A1, eNOS, iNOS and heat shock protein 90 (hsp90), and production of PGI(2), PGE(2), 20-HETE and NO. Piroxicam 56-65 nitric oxide synthase 3 Rattus norvegicus 203-207 21463481-12 2011 These data suggest that a decrease in the expression and activity of COX-2 and iNOS associated with an increase in CYP4A1 expression and 20-HETE synthesis contributes to the effect of piroxicam to prevent the hypotension during rat endotoxaemia. Piroxicam 184-193 cytochrome c oxidase II, mitochondrial Rattus norvegicus 69-74 21463481-4 2011 The aim of this study was to investigate the effects of piroxicam, a preferential COX-1 inhibitor, on the endotoxin-induced changes in blood pressure, expression of COX-1, inducible COX (COX-2), CYP4A1, eNOS, iNOS and heat shock protein 90 (hsp90), and production of PGI(2), PGE(2), 20-HETE and NO. Piroxicam 56-65 nitric oxide synthase 2 Rattus norvegicus 209-213 21463481-12 2011 These data suggest that a decrease in the expression and activity of COX-2 and iNOS associated with an increase in CYP4A1 expression and 20-HETE synthesis contributes to the effect of piroxicam to prevent the hypotension during rat endotoxaemia. Piroxicam 184-193 nitric oxide synthase 2 Rattus norvegicus 79-83 21463481-4 2011 The aim of this study was to investigate the effects of piroxicam, a preferential COX-1 inhibitor, on the endotoxin-induced changes in blood pressure, expression of COX-1, inducible COX (COX-2), CYP4A1, eNOS, iNOS and heat shock protein 90 (hsp90), and production of PGI(2), PGE(2), 20-HETE and NO. Piroxicam 56-65 heat shock protein 90 alpha family class A member 1 Rattus norvegicus 218-239 21463481-12 2011 These data suggest that a decrease in the expression and activity of COX-2 and iNOS associated with an increase in CYP4A1 expression and 20-HETE synthesis contributes to the effect of piroxicam to prevent the hypotension during rat endotoxaemia. Piroxicam 184-193 cytochrome P450, family 4, subfamily a, polypeptide 1 Rattus norvegicus 115-121 21463481-4 2011 The aim of this study was to investigate the effects of piroxicam, a preferential COX-1 inhibitor, on the endotoxin-induced changes in blood pressure, expression of COX-1, inducible COX (COX-2), CYP4A1, eNOS, iNOS and heat shock protein 90 (hsp90), and production of PGI(2), PGE(2), 20-HETE and NO. Piroxicam 56-65 heat shock protein 90 alpha family class A member 1 Rattus norvegicus 241-246 21858171-0 2011 Apoptosis induced by piroxicam plus cisplatin combined treatment is triggered by p21 in mesothelioma. Piroxicam 21-30 H3 histone pseudogene 16 Homo sapiens 81-84 21682312-5 2011 Phospholipase A2 was shown to be sensitive to the presence of the drugs in the systems studied; the activity of the enzyme correlates with the effect of meloxicam, piroxicam, and tenoxicam on the monolayer properties. Piroxicam 164-173 phospholipase A2 group IB Homo sapiens 0-16 22707821-3 2011 The apparent first-order rate constants for the photochemical and thermal degradation of piroxicam have been determined as 2.04-10.01 and 0.86-3.06x10(-3) min(-1), respectively. Piroxicam 89-98 CD59 molecule (CD59 blood group) Homo sapiens 155-161 21858171-6 2011 Here we show that apoptotic increase following combined treatment is mediated by p21, since apoptotic increase in piroxicam/cisplatin combined treatment is abolished upon p21 silencing. Piroxicam 114-123 H3 histone pseudogene 16 Homo sapiens 81-84 21858171-6 2011 Here we show that apoptotic increase following combined treatment is mediated by p21, since apoptotic increase in piroxicam/cisplatin combined treatment is abolished upon p21 silencing. Piroxicam 114-123 H3 histone pseudogene 16 Homo sapiens 171-174 21858171-7 2011 CONCLUSIONS/SIGNIFICANCE: Piroxicam/cisplatin combined treatment determines an apoptosis increase in MM cells, which is dependent on the p21 expression. Piroxicam 26-35 H3 histone pseudogene 16 Homo sapiens 137-140 21858171-8 2011 The results provided suggest that piroxicam/cisplatin combination might be tested in clinical settings in tumor specimens that express p21. Piroxicam 34-43 H3 histone pseudogene 16 Homo sapiens 135-138 20848493-4 2010 METHODS: Colitis was triggered in Il10(-/-) mice by exposure to the non-steroidal anti-inflammatory drug piroxicam. Piroxicam 105-114 interleukin 10 Mus musculus 34-38 19930539-10 2010 The PROK1-evoked Cl- secretion is reduced by piroxicam (non-selective cyclooxygenase inhibitor), and a prostaglandin EP(4) receptor antagonist (AH23848), but not a thromboxane receptor antagonist (GR32191B). Piroxicam 45-54 prokineticin 1 Rattus norvegicus 4-9 20036014-8 2010 The mixed COX-1/COX-2 inhibitor piroxicam blocked PGD2 and PGE2 production, but upregulated LTC4 following treatment while tepoxilan (Zubrin), a pan COX/LOX inhibitor, markedly reduced the production of all eicosanoids. Piroxicam 32-41 cytochrome c oxidase subunit I Canis lupus familiaris 10-15 20036014-8 2010 The mixed COX-1/COX-2 inhibitor piroxicam blocked PGD2 and PGE2 production, but upregulated LTC4 following treatment while tepoxilan (Zubrin), a pan COX/LOX inhibitor, markedly reduced the production of all eicosanoids. Piroxicam 32-41 cytochrome c oxidase subunit II Canis lupus familiaris 16-21 20036014-8 2010 The mixed COX-1/COX-2 inhibitor piroxicam blocked PGD2 and PGE2 production, but upregulated LTC4 following treatment while tepoxilan (Zubrin), a pan COX/LOX inhibitor, markedly reduced the production of all eicosanoids. Piroxicam 32-41 lysyl oxidase Canis lupus familiaris 153-156 20665602-5 2010 The results showed that after the endothelial cells were incubated with 250 muM of hydrogen peroxide for 12 h, apoptosis increased, which was antagonized by the cyclooxygenase-2 inhibitor nimesulide or the nonselective cyclooxygenase inhibitor aspirin, but not by the cyclooxygenase-1 inhibitor piroxicam. Piroxicam 295-304 prostaglandin-endoperoxide synthase 2 Homo sapiens 161-177 19931610-9 2010 A selective COX-1 inhibitor, piroxicam, but not the selective COX-2 inhibitor, nimesulide, reversed the LPS-induced behavioural changes without affecting IL-6, IL-1beta and TNF-alpha protein expression levels in the periphery or mRNA levels in the hippocampus. Piroxicam 29-38 cytochrome c oxidase I, mitochondrial Mus musculus 12-17 20529813-1 2010 Unusual expression of interleukin-1alpha, -1beta and -6 was previously found in the epiphyseal cartilage of rat fetuses prenatally exposed to various non-steroidal anti-inflammatory drugs (NSAID, i.e., ibuprofen, piroxicam, tolmetin) and selective cyclooxygenase-2 inhibitor (DFU). Piroxicam 213-222 interleukin 1 alpha Rattus norvegicus 22-55 20000874-2 2010 Piroxicam is a nonselective nonsteroidal anti-inflammatory drug that blocks the activity of COX-1 and COX-2. Piroxicam 0-9 mitochondrially encoded cytochrome c oxidase I Homo sapiens 92-97 20000874-2 2010 Piroxicam is a nonselective nonsteroidal anti-inflammatory drug that blocks the activity of COX-1 and COX-2. Piroxicam 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 102-107 18340641-5 2008 METHODS: Colitis was induced in IL-10-/- mice by administering piroxicam for two weeks. Piroxicam 63-72 interleukin 10 Mus musculus 32-37 19422321-1 2009 Polymorphisms in CYP2C8 and CYP2C9 are common in all the human populations and many CYP2C8 and CYP2C9 gene variations cause decreased enzyme activity towards the NSAIDs aceclofenac, celecoxib, diclofenac, ibuprofen, indomethazine, lornoxicam, meloxicam, naproxen, piroxicam, tenoxicam and valdecoxib. Piroxicam 264-273 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 17-23 19422321-1 2009 Polymorphisms in CYP2C8 and CYP2C9 are common in all the human populations and many CYP2C8 and CYP2C9 gene variations cause decreased enzyme activity towards the NSAIDs aceclofenac, celecoxib, diclofenac, ibuprofen, indomethazine, lornoxicam, meloxicam, naproxen, piroxicam, tenoxicam and valdecoxib. Piroxicam 264-273 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 28-34 19422321-1 2009 Polymorphisms in CYP2C8 and CYP2C9 are common in all the human populations and many CYP2C8 and CYP2C9 gene variations cause decreased enzyme activity towards the NSAIDs aceclofenac, celecoxib, diclofenac, ibuprofen, indomethazine, lornoxicam, meloxicam, naproxen, piroxicam, tenoxicam and valdecoxib. Piroxicam 264-273 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 84-90 19422321-1 2009 Polymorphisms in CYP2C8 and CYP2C9 are common in all the human populations and many CYP2C8 and CYP2C9 gene variations cause decreased enzyme activity towards the NSAIDs aceclofenac, celecoxib, diclofenac, ibuprofen, indomethazine, lornoxicam, meloxicam, naproxen, piroxicam, tenoxicam and valdecoxib. Piroxicam 264-273 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 95-101 19067430-9 2009 C57BL/6.mdr1a-deficient mice treated with piroxicam or infected with H. bilis showed no weight loss, or alterations in colonic histology. Piroxicam 42-51 ATP-binding cassette, sub-family B (MDR/TAP), member 1A Mus musculus 8-13 19139781-9 2009 Adjunct use of silymarin with piroxicam results in significant reduction in both cytokines (IL-1 alpha and IL-8), and serum levels of C3 and C4. Piroxicam 30-39 interleukin 1 alpha Homo sapiens 92-102 19139781-9 2009 Adjunct use of silymarin with piroxicam results in significant reduction in both cytokines (IL-1 alpha and IL-8), and serum levels of C3 and C4. Piroxicam 30-39 C-X-C motif chemokine ligand 8 Homo sapiens 107-111 19139781-9 2009 Adjunct use of silymarin with piroxicam results in significant reduction in both cytokines (IL-1 alpha and IL-8), and serum levels of C3 and C4. Piroxicam 30-39 complement C4A (Rodgers blood group) Homo sapiens 134-143 18604228-10 2008 Finally, responses to basolateral BK in intact tissues were inhibited by tetrodotoxin (1 microM), atropine (1 microM), capsaicin (100 microM) and piroxicam (10 microM). Piroxicam 146-155 kininogen 1 Homo sapiens 34-36 19815627-4 2009 Significant inflammation was induced in the ileum of SAMP1/Yit mice at 23 wk of age after piroxicam treatment for 3 wk. Piroxicam 90-99 transmembrane protein 201 Mus musculus 53-58 19723114-10 2009 While treatment with 10 micromol/L celecoxib or 10 micromol/L piroxicam significantly suppressed the activity of COX enzymes, neither agent affected the growth of A431 and SW962 cells at this concentration. Piroxicam 62-71 cytochrome c oxidase subunit 8A Homo sapiens 113-116 19446544-0 2009 Piroxicam accelerates development of colitis in T-cell receptor alpha chain-deficient mice. Piroxicam 0-9 T cell receptor alpha chain Mus musculus 48-75 19446544-2 2009 We have demonstrated that piroxicam induces colitis in non-colitic TCR.alpha-deficient mice, but not wild-type mice, within 14 days. Piroxicam 26-35 T cell receptor alpha chain Mus musculus 67-76 18974013-14 2009 IL-6 neutralizing antibodies and piroxicam inhibited the decrease OPG expression, but did not modify RANKL mRNA level, indicating that IL-6 and PGE(2) induce a decrease of the OPG/RANKL ratio. Piroxicam 33-42 tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin) Mus musculus 66-69 18974013-14 2009 IL-6 neutralizing antibodies and piroxicam inhibited the decrease OPG expression, but did not modify RANKL mRNA level, indicating that IL-6 and PGE(2) induce a decrease of the OPG/RANKL ratio. Piroxicam 33-42 interleukin 6 Mus musculus 135-139 18974013-14 2009 IL-6 neutralizing antibodies and piroxicam inhibited the decrease OPG expression, but did not modify RANKL mRNA level, indicating that IL-6 and PGE(2) induce a decrease of the OPG/RANKL ratio. Piroxicam 33-42 tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin) Mus musculus 176-179 19521782-4 2009 Additionally, dissolution of piroxicam in the samples at C/P mole ratios of 10:1, 20:1, 30:1, 40:1, and 52.5:1 was investigated at pH 1.2 and pH 4. Piroxicam 29-38 prolyl 4-hydroxylase, transmembrane Homo sapiens 142-146 19521782-9 2009 The dissolution of piroxicam at pH 4 is lower than that at pH 1.2. Piroxicam 19-28 prolyl 4-hydroxylase, transmembrane Homo sapiens 32-36 19521782-9 2009 The dissolution of piroxicam at pH 4 is lower than that at pH 1.2. Piroxicam 19-28 alanine--glyoxylate and serine--pyruvate aminotransferase Homo sapiens 59-63 18536750-6 2008 EXPERIMENTAL APPROACH: Dextran sodium sulphate (DSS)-treated mice and piroxicam-treated IL-10-/- mice were used as animal models of colitis. Piroxicam 70-79 interleukin 10 Mus musculus 88-93 18536750-9 2008 The administration of ATL-801 prevented weight loss, suppressed the inflammatory infiltrate into colonic mucosa and decreased epithelial hyperplasia in piroxicam-treated IL-10-/- mice. Piroxicam 152-161 interleukin 10 Mus musculus 170-175 18441396-10 2008 Piroxicam, predominantly constitutive cyclooxygenase (COX-1) inhibitor, given i.p. Piroxicam 0-9 cytochrome c oxidase I, mitochondrial Rattus norvegicus 54-59 18225536-0 2007 Piroxicam increases colon tumorigenesis and promotes apoptosis in Mlh1 +/- /Apc1638(N/+) mice. Piroxicam 0-9 mutL homolog 1 Mus musculus 66-70 18031725-2 2008 Here we describe pharmacological characterization of a novel prostanoid EP(4) receptor antagonist, CJ-042,794 (4-{(1S)-1-[({5-chloro-2-[(4-fluorophenyl) oxy] phenyl} carbonyl) amino] ethyl} benzoic acid) in comparison with piroxicam (non-steroidal anti-inflammatory drug) or rofecoxib (cyclooxygenase-2 inhibitor). Piroxicam 223-232 prostaglandin E receptor 4 Rattus norvegicus 61-86 17998749-0 2007 Post-chemiluminescence phenomenon of NBS-luminol reactions and their applications to flow injection analysis of piroxicam. Piroxicam 112-121 nibrin Homo sapiens 37-40 17998749-1 2007 A new post-chemiluminescence (PCL) reaction was observed when piroxicam was injected into the reaction mixture after the CL reaction of N-bromosuccinimide (NBS) and luminol. Piroxicam 62-71 nibrin Homo sapiens 156-159 20641566-18 2004 The specific binding site II on HSA is located in a hydrophobic cavity of 8-10 A in diameter and has been a preferential binding site for many ligands, such as fenbufen, diazepam, and piroxicam, in drug designs (5). Piroxicam 184-193 albumin Homo sapiens 32-35 17275371-5 2008 Expression of canine NAG-1 was increased by treatment with piroxicam and SC-560 (NSAIDs) and the PPARgamma ligand rosiglitazone. Piroxicam 59-68 growth differentiation factor 15 Homo sapiens 21-26 18225536-1 2007 BACKGROUND: The present study examines the effect of piroxicam, a non-steroidal anti-inflammatory drug, on tumor development in Mlh1+/- /Apc1638(N/+) mice, in a preclinical model of human colon cancer. Piroxicam 53-62 mutL homolog 1 Mus musculus 128-132 17692291-0 2007 The non-steroidal anti-inflammatory drug piroxicam blocks ligand binding to the formyl peptide receptor but not the formyl peptide receptor like 1. Piroxicam 41-50 formyl peptide receptor 1 Homo sapiens 80-103 17692291-5 2007 Piroxicam reduced the neutrophil superoxide production induced by the FPR agonist but had no significant effect on the FPRL1 induced response. Piroxicam 0-9 formyl peptide receptor 1 Homo sapiens 70-73 17692287-0 2007 Embryonic stem cells ameliorate piroxicam-induced colitis in IL10-/- KO mice. Piroxicam 32-41 interleukin 10 Mus musculus 61-65 17692287-2 2007 Colitis, induced in IL10-/- KO mice using piroxicam, was associated with the increased levels of IL-12. Piroxicam 42-51 interleukin 10 Mus musculus 20-24 17692291-3 2007 We have compared the effects of piroxicam on superoxide production mediated by two closely related G-protein coupled receptors expressed on neutrophils, the formyl peptide receptor (FPR) and the formyl peptide receptor like 1 (FPRL1). Piroxicam 32-41 formyl peptide receptor 1 Homo sapiens 157-180 17692291-6 2007 Neutrophil intracellular calcium changes induced by the agonist WKYMVm (that triggers both FPR and FPRL1) were only inhibited by piroxicam when the drug was combined with the FPRL1 specific antagonist, Trp-Arg-Trp-Trp-Trp-Trp (WRW(4)), and this was true also for the inhibition of superoxide anion release. Piroxicam 129-138 formyl peptide receptor 1 Homo sapiens 91-94 17506539-1 2007 We report on steady-state and ps-time-resolved emission studies of piroxicam (1) drug within human serum albumin (HSA) protein in cyclodextrin and in neat solvents. Piroxicam 67-76 albumin Homo sapiens 99-118 17692291-6 2007 Neutrophil intracellular calcium changes induced by the agonist WKYMVm (that triggers both FPR and FPRL1) were only inhibited by piroxicam when the drug was combined with the FPRL1 specific antagonist, Trp-Arg-Trp-Trp-Trp-Trp (WRW(4)), and this was true also for the inhibition of superoxide anion release. Piroxicam 129-138 formyl peptide receptor 2 Homo sapiens 175-180 17692291-7 2007 Receptor-binding analysis showed that the fluorescently labelled FPR specific ligand N-formyl-Nle-Leu-Phe-Nle-Tyr-Lys (fNLFNYK), was competed for in a dose-dependent manner, by the FPR ligand fMLF and as well as by piroxicam. Piroxicam 215-224 formyl peptide receptor 1 Homo sapiens 65-68 17692291-7 2007 Receptor-binding analysis showed that the fluorescently labelled FPR specific ligand N-formyl-Nle-Leu-Phe-Nle-Tyr-Lys (fNLFNYK), was competed for in a dose-dependent manner, by the FPR ligand fMLF and as well as by piroxicam. Piroxicam 215-224 formyl peptide receptor 1 Homo sapiens 181-184 17692291-8 2007 We show that piroxicam inhibits the neutrophil responses triggered through FPR, but not through FPRL1 and this inhibition is due to a reduced binding of the activating ligand to its cell surface receptor. Piroxicam 13-22 formyl peptide receptor 1 Homo sapiens 75-78 17408649-7 2007 Furthermore, Rspo1 substantially decreased the histopathologic severity of chronic enterocolitis by repairing crypt epithelium and simultaneously suppressing inflammatory infiltration in piroxicam-exposed IL-10(-/-) mice. Piroxicam 187-196 R-spondin 1 Mus musculus 13-18 17306218-0 2007 Interaction of piroxicam with mitochondrial membrane and cytochrome c. Piroxicam 15-24 cytochrome c Cricetulus griseus 57-69 17306218-3 2007 In this work, we present the interaction of piroxicam, a long acting Non-Steroidal Anti-Inflammatory Drug (NSAID) with isolated mitochondria, membrane mimetic systems, intact cells and a mitochondrial protein cytochrome c. Piroxicam 44-53 cytochrome c Cricetulus griseus 209-221 17306218-7 2007 In intact cells viz., V79 Chinese Hamster lung fibroblast, piroxicam is capable of releasing cytochrome c from mitochondria into the cytosol in a dose dependent manner along with the enhancement of downstream proapoptotic event viz., increase in caspase-3 activity. Piroxicam 59-68 cytochrome c Cricetulus griseus 93-105 17306218-7 2007 In intact cells viz., V79 Chinese Hamster lung fibroblast, piroxicam is capable of releasing cytochrome c from mitochondria into the cytosol in a dose dependent manner along with the enhancement of downstream proapoptotic event viz., increase in caspase-3 activity. Piroxicam 59-68 caspase-3 Cricetulus griseus 246-255 17306218-8 2007 We have also shown that piroxicam can reduce cytochrome c within a time frame relevant to its lifetime in blood plasma. Piroxicam 24-33 cytochrome c Cricetulus griseus 45-57 17306218-10 2007 CD spectroscopy shows that small but significant changes occur in the structure of cytochrome c when reduced by piroxicam. Piroxicam 112-121 cytochrome c Cricetulus griseus 83-95 17408649-7 2007 Furthermore, Rspo1 substantially decreased the histopathologic severity of chronic enterocolitis by repairing crypt epithelium and simultaneously suppressing inflammatory infiltration in piroxicam-exposed IL-10(-/-) mice. Piroxicam 187-196 interleukin 10 Mus musculus 205-210 17005917-7 2007 Salicylate, piroxicam, ibuprofen, naproxen, sulindac, tolmetin, and etodolac inhibited MRP2- and MRP4-mediated MTX transport according to a one-site competition model. Piroxicam 12-21 ATP binding cassette subfamily C member 2 Homo sapiens 87-91 17383864-8 2007 The average peak serum piroxicam concentration (948 ng/ml, which inhibited cox-2 activity) and serum half-life (15.9 h) were similar to that in normal cats. Piroxicam 23-32 prostaglandin-endoperoxide synthase 2 Felis catus 75-80 17328244-3 2007 NSAIDs tested significantly enhanced TNF-alpha release from lipopolysaccharide (LPS)-activated RAW264.7 cells at certain concentrations (fenoprofen, indomethacin, piroxicam, aceclofenac, diclofenac and sulindac) or in a dose-dependent manner (aspirin and phenylbutazone). Piroxicam 163-172 tumor necrosis factor Mus musculus 37-46 17005917-7 2007 Salicylate, piroxicam, ibuprofen, naproxen, sulindac, tolmetin, and etodolac inhibited MRP2- and MRP4-mediated MTX transport according to a one-site competition model. Piroxicam 12-21 ATP binding cassette subfamily C member 4 Homo sapiens 97-101 17112811-0 2006 Impact of CYP2C9*3/*3 genotype on the pharmacokinetics and pharmacodynamics of piroxicam. Piroxicam 79-88 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 10-16 17073578-7 2006 Nimesulide, meclofenamate, and piroxicam were more selective towards SULT1A1 inhibition, while sulindac and ibuprofen were more selective towards SULT1E1 inhibition. Piroxicam 31-40 sulfotransferase family 1A member 1 Homo sapiens 69-76 17062690-8 2006 Of note, epidermal growth factor receptor, one of the new biological targets of chemotherapy for mesothelioma, was down-regulated and HtrA1, a serine protease recently shown to be an endogenous mediator of CDDP cytotoxicity, was up-regulated following piroxicam treatment both in vitro and in vivo. Piroxicam 252-261 epidermal growth factor receptor Homo sapiens 9-41 17062690-8 2006 Of note, epidermal growth factor receptor, one of the new biological targets of chemotherapy for mesothelioma, was down-regulated and HtrA1, a serine protease recently shown to be an endogenous mediator of CDDP cytotoxicity, was up-regulated following piroxicam treatment both in vitro and in vivo. Piroxicam 252-261 HtrA serine peptidase 1 Homo sapiens 134-139 17438921-0 2006 Morphological changes in the liver after the administration of piroxicam and its complexes with Bio-Ions Cu (II), Co (II), Zn (II) to the rats. Piroxicam 63-72 cytochrome c oxidase II, mitochondrial Rattus norvegicus 114-121 17438921-1 2006 In this research we present the results of the liver histopathological examinations after the administration of the Piroxicam (Pirox) and its complex combinations with metal bio-ions Cu (II), Co (II), Zn (II) to rats (White Wistar, 150-180 gr.). Piroxicam 116-125 cytochrome c oxidase II, mitochondrial Rattus norvegicus 192-199 17438921-1 2006 In this research we present the results of the liver histopathological examinations after the administration of the Piroxicam (Pirox) and its complex combinations with metal bio-ions Cu (II), Co (II), Zn (II) to rats (White Wistar, 150-180 gr.). Piroxicam 116-121 cytochrome c oxidase II, mitochondrial Rattus norvegicus 192-199 17017983-10 2006 Tenoxicam and piroxicam known as COX-1 inhibitors demonstrated higher partition capacity in liposomes/water systems together with a smaller ability to change the membrane fluidity and surface potential. Piroxicam 14-23 mitochondrially encoded cytochrome c oxidase I Homo sapiens 33-38 16444599-3 2006 Non-steroidal anti-inflammatory drugs (NSAIDS), piroxicam, aspirin, ibuprofen, naproxen and celecoxib all specifically inhibited tNOX activity of HeLa (human cervical carcinoma) and BT-20 (human mammary carcinoma) cells (IC(50) in the nanomolar range) without effect on ECTO-NOX activities of non-cancer MCF-10A mammary epithelial cells. Piroxicam 48-57 ecto-NOX disulfide-thiol exchanger 2 Homo sapiens 129-133 17022718-11 2006 The risk for digestive hemorrhage associated with the CYP2C9 genotype is particularly relevant when using aceclofenac, celecoxib, diclofenac, ibuprofen, indomethacin, lornoxicam, piroxicam, or naproxen. Piroxicam 179-188 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 54-60 16825660-9 2006 CD8+ T cells were needed for worms to reverse piroxicam-induced colitis in Rag mice (T and B cell deficient) reconstituted with IL-10-/- T cells. Piroxicam 46-55 interleukin 10 Mus musculus 128-133 16444599-3 2006 Non-steroidal anti-inflammatory drugs (NSAIDS), piroxicam, aspirin, ibuprofen, naproxen and celecoxib all specifically inhibited tNOX activity of HeLa (human cervical carcinoma) and BT-20 (human mammary carcinoma) cells (IC(50) in the nanomolar range) without effect on ECTO-NOX activities of non-cancer MCF-10A mammary epithelial cells. Piroxicam 48-57 tripartite motif containing 33 Homo sapiens 270-274 16505106-10 2006 Celecoxib or piroxicam treatment in athymic mice significantly delayed progression of HT1376 xenografts, which express COX-2, but not UMUC3 xenografts that lack COX-2 expression. Piroxicam 13-22 cytochrome c oxidase II, mitochondrial Mus musculus 119-124 16505106-10 2006 Celecoxib or piroxicam treatment in athymic mice significantly delayed progression of HT1376 xenografts, which express COX-2, but not UMUC3 xenografts that lack COX-2 expression. Piroxicam 13-22 cytochrome c oxidase II, mitochondrial Mus musculus 161-166 16118328-8 2005 In contrast, CYP2C9 genotype is expected to impact the clearance of ibuprofen, indomethacin, flurbiprofen, celecoxib, valdecoxib, lornoxicam, tenoxicam, meloxicam, and piroxicam. Piroxicam 168-177 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 13-19 16306768-1 2005 Treatment with the nonsteroidal anti-inflammatory drugs piroxicam or sulindac was recently shown to accelerate the development of colitis in interleukin (IL)-10-deficient (IL-10) mice. Piroxicam 56-65 interleukin 10 Mus musculus 172-177 16306768-3 2005 In this study, the effects of piroxicam on the colonic mucosa of IL-10 C57BL/6 mice were evaluated histologically. Piroxicam 30-39 interleukin 10 Mus musculus 65-70 16306768-6 2005 In vivo treatment of C57BL/6 IL-10 mice with oral piroxicam markedly enhanced apoptosis of colonic epithelium and resulted in focal erosion of the mucosal surface, enhanced bacterial adhesion and invasion, and accelerated the development of colitis. Piroxicam 50-59 interleukin 10 Mus musculus 29-34 15951234-2 2005 Ternary Fe(III), Co(II), Ni(II), Cu(II), Zn(II) and UO2(II) complexes with piroxicam (Pir) drug (H2L1) and dl-alanine (Ala) (HL2) and also the binary UO2(II) complex with Pir were studied. Piroxicam 75-84 mitochondrially encoded cytochrome c oxidase II Homo sapiens 17-23 16239272-11 2005 The PTGS inhibitor piroxicam, administered in doses that inhibited PTGS1 but not PTGS2, significantly prolonged gestation. Piroxicam 19-28 prostaglandin G/H synthase 1 Cavia porcellus 67-72 16198655-0 2005 Influence of CYP2C9 genotypes on the pharmacokinetics and pharmacodynamics of piroxicam. Piroxicam 78-87 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 13-19 16198655-1 2005 OBJECTIVE: Our objective was to evaluate the influence of cytochrome P450 (CYP) 2C9 polymorphisms on the pharmacokinetics and pharmacodynamics of the nonsteroidal anti-inflammatory drug piroxicam. Piroxicam 186-195 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 58-83 16198655-8 2005 CONCLUSION: Piroxicam"s oral clearance was impaired and its inhibitory effect on cyclooxygenase 1 activity was increased in CYP2C9*1/*2 or CYP2C9*1/*3 individuals, as compared with CYP2C 9*1 homozygous individuals. Piroxicam 12-21 prostaglandin-endoperoxide synthase 1 Homo sapiens 81-97 16198655-8 2005 CONCLUSION: Piroxicam"s oral clearance was impaired and its inhibitory effect on cyclooxygenase 1 activity was increased in CYP2C9*1/*2 or CYP2C9*1/*3 individuals, as compared with CYP2C 9*1 homozygous individuals. Piroxicam 12-21 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 124-130 16198655-8 2005 CONCLUSION: Piroxicam"s oral clearance was impaired and its inhibitory effect on cyclooxygenase 1 activity was increased in CYP2C9*1/*2 or CYP2C9*1/*3 individuals, as compared with CYP2C 9*1 homozygous individuals. Piroxicam 12-21 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 139-145 16198655-8 2005 CONCLUSION: Piroxicam"s oral clearance was impaired and its inhibitory effect on cyclooxygenase 1 activity was increased in CYP2C9*1/*2 or CYP2C9*1/*3 individuals, as compared with CYP2C 9*1 homozygous individuals. Piroxicam 12-21 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 181-188 15962179-9 2005 We found that NSAIDs inhibited both the peroxidation and chlorinating activity of MPO as follows: diclofenac (36 +/- 10, 45 +/- 3%), indomethacin (97 +/- 2, 100 +/- 1%), naproxen (56 +/- 8, 76 +/- 3%), piroxicam (77 +/- 5, 99 +/- 1%), and tenoxicam (90 +/- 2, 100 +/- 1%), respectively (N = 3). Piroxicam 202-211 myeloperoxidase Rattus norvegicus 82-85 16052542-3 2005 The effect of shell thickness on release of a model drug, piroxicam, has been clearly shown for 2- to 15-microm thick shells of poly(D,L-lactide) (PDLL) surrounding a poly(D,L-lactide-co-glycolide) (PLG) core and compared to pure PLG microspheres loaded with piroxicam. Piroxicam 58-67 plasminogen Homo sapiens 199-202 16052542-3 2005 The effect of shell thickness on release of a model drug, piroxicam, has been clearly shown for 2- to 15-microm thick shells of poly(D,L-lactide) (PDLL) surrounding a poly(D,L-lactide-co-glycolide) (PLG) core and compared to pure PLG microspheres loaded with piroxicam. Piroxicam 58-67 plasminogen Homo sapiens 230-233 15936249-6 2005 Bromelain also significantly decreased the clinical and histologic severity of colonic inflammation when administered to piroxicam-exposed IL-10-/- mice with established colitis. Piroxicam 121-130 interleukin 10 Mus musculus 139-144 15996031-6 2005 Increments of MPO and MDA contents, as well as a decrease in GSH levels were detected in the gastric mucosa of indomethacin- or piroxicam-treated animals. Piroxicam 128-137 myeloperoxidase Rattus norvegicus 14-17 16080005-10 2005 Increments of MPO and MDA contents, as well as a decrease in GSH levels, were detected in the gastric mucosa of indomethacin-, piroxicam- or ketoprofen-treated animals. Piroxicam 127-136 myeloperoxidase Rattus norvegicus 14-17 15990687-8 2005 The dose-dependent inhibitory effect of dexamethasone on MMP-2 activity was significantly less than that of the tested NSAIDs at concentrations of 10-80 microg/ml, while it increased at doses of >100 microg/ml compared with piroxicam. Piroxicam 227-236 matrix metallopeptidase 2 Mus musculus 57-62 19379215-3 2005 A phase II clinical trial of carboplatin combined with the cox inhibitor, piroxicam, was performed in 31 dogs with naturally occurring, histopathologically confirmed, measurable TCC. Piroxicam 74-83 prostaglandin-endoperoxide synthase 1 Canis lupus familiaris 59-62 19379215-10 2005 In conclusion, carboplatin/piroxicam induced remission in 40% of dogs providing evidence that a cox inhibitor enhances the antitumour activity of carboplatin. Piroxicam 27-36 prostaglandin-endoperoxide synthase 1 Canis lupus familiaris 96-99 15773062-3 2005 In this study, a model is developed to independently determine the contributions of each of these factors by fitting the release of piroxicam from monodisperse 50-microm microspheres made with PLG of different initial molecular weights. Piroxicam 132-141 plasminogen Homo sapiens 193-196 15555568-2 2004 NAG-1 expression was increased by diclofenac, aceclofenac, indomethacin, ibuprofen, and sulindac sulfide, in the order of NAG-1 induction, but not by acetaminophen, piroxicam or NS-398. Piroxicam 165-174 growth differentiation factor 15 Homo sapiens 0-5 15824018-5 2005 Dexamethasone and piroxicam reduced the multiplicity of colon and lung tumors in A/J and AC3 mice, demonstrating the advantage of a combined colon and lung bioassay. Piroxicam 18-27 adenylate cyclase 3 Mus musculus 89-92 15892673-4 2005 Non-selective cyclooxygenase-1 (COX-1) inhibitors used in periodontal research include compounds such as aspirin, flurbiprofen, ibuprofen, naproxen and piroxicam. Piroxicam 152-161 prostaglandin-endoperoxide synthase 1 Homo sapiens 14-30 15892673-4 2005 Non-selective cyclooxygenase-1 (COX-1) inhibitors used in periodontal research include compounds such as aspirin, flurbiprofen, ibuprofen, naproxen and piroxicam. Piroxicam 152-161 mitochondrially encoded cytochrome c oxidase I Homo sapiens 32-37 16607851-0 2005 A comparative study regarding the morphological alteration on the gastric level after the administration of piroxicam and complexes with bio-ions Cu(II), Co(II), Zn(II) to rats. Piroxicam 108-117 cytochrome c oxidase II, mitochondrial Rattus norvegicus 154-160 16607851-1 2005 The complex combinations of Piroxicam (Pirox) with the metallic bio-ions: Cu(II), Co(II), Zn(II) have been obtained and defined in a previous stage by physical-chemical methods (IR, X, SM, CSS-UV, DTA, DTG), an toxicological and biochemical aspect. Piroxicam 28-37 cytochrome c oxidase II, mitochondrial Rattus norvegicus 82-88 16607851-1 2005 The complex combinations of Piroxicam (Pirox) with the metallic bio-ions: Cu(II), Co(II), Zn(II) have been obtained and defined in a previous stage by physical-chemical methods (IR, X, SM, CSS-UV, DTA, DTG), an toxicological and biochemical aspect. Piroxicam 28-33 cytochrome c oxidase II, mitochondrial Rattus norvegicus 82-88 15284281-7 2004 The inhibition of interleukin-2 by anandamide and arachidonic acid was partially reversed by pretreatment with the nonspecific cyclooxygenase inhibitors, flurbiprofen and piroxicam. Piroxicam 171-180 interleukin 2 Mus musculus 18-31 15613736-3 2004 The muscarinic agent - carbachol-induced HPA response was considerably supressed by piroxicam, a predominantly constitutive cyclooxygenase (COX-1) inhibitor and significantly diminished by indomethacin, a non-selective COX blocker, but was unaffected by compound NS-398, an inducible cyclooxygenase (COX-2) antagonist. Piroxicam 84-93 mitochondrially encoded cytochrome c oxidase I Homo sapiens 140-145 15613736-3 2004 The muscarinic agent - carbachol-induced HPA response was considerably supressed by piroxicam, a predominantly constitutive cyclooxygenase (COX-1) inhibitor and significantly diminished by indomethacin, a non-selective COX blocker, but was unaffected by compound NS-398, an inducible cyclooxygenase (COX-2) antagonist. Piroxicam 84-93 mitochondrially encoded cytochrome c oxidase II Homo sapiens 300-305 15613736-5 2004 The nicotine-induced increase in ACTH and corticosterone response was significantly supressed by piroxicam, and diminished by indomethacin, but was significantly augmented by L-NAME and L-NNA. Piroxicam 97-106 proopiomelanocortin Homo sapiens 33-37 15613736-14 2004 histamine- and HTMT, a histamine H(1)-agonist-induced ACTH and corticosterone response were significantly diminished by piroxicam and indomethacin, respectively. Piroxicam 120-129 proopiomelanocortin Homo sapiens 54-58 15198222-6 2004 RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than COX-1. Piroxicam 79-88 prostaglandin-endoperoxide synthase 1 Canis lupus familiaris 119-122 15673949-1 2004 AIM: to know the effect of piroxicam (COX-1 and COX-2 inhibitor NSAID) and meloxicam (selective COX-2 inhibitor NSAID) against the gastric mucosa. Piroxicam 27-36 mitochondrially encoded cytochrome c oxidase I Homo sapiens 38-43 15368285-3 2004 IL-10(-/-) mice given piroxicam develop severe and persistent colitis. Piroxicam 22-31 interleukin 10 Mus musculus 0-5 15368285-6 2004 Colonization of piroxicam-treated colitic IL-10(-/-) mice with Heligmosomoides polygyrus (an intestinal helminth) suppressed established inflammation and inhibited mucosal IL-12 and IFN-gamma production. Piroxicam 16-25 interleukin 10 Mus musculus 42-47 15368285-6 2004 Colonization of piroxicam-treated colitic IL-10(-/-) mice with Heligmosomoides polygyrus (an intestinal helminth) suppressed established inflammation and inhibited mucosal IL-12 and IFN-gamma production. Piroxicam 16-25 interferon gamma Mus musculus 182-191 15464832-8 2004 In contrast, piroxicam, an unspecific COX inhibitor which displays an increased selectivity towards COX-1, only prevented secondary hyperalgesia to formalin at a high dose following spinal administration. Piroxicam 13-22 cytochrome c oxidase I, mitochondrial Rattus norvegicus 100-105 15307162-5 2004 The presence of the PL shell enveloping a PLG core essentially eliminated the initial "burst" of piroxicam that was observed when the drug was released from pure PLG microspheres. Piroxicam 97-106 plasminogen Homo sapiens 42-45 15307162-5 2004 The presence of the PL shell enveloping a PLG core essentially eliminated the initial "burst" of piroxicam that was observed when the drug was released from pure PLG microspheres. Piroxicam 97-106 plasminogen Homo sapiens 162-165 15309881-6 2004 Myeloperoxidase activity as an index of neutrophil infiltration was elevated with celecoxib and piroxicam on normal gastric mucosa. Piroxicam 96-105 myeloperoxidase Rattus norvegicus 0-15 15009511-6 2004 Furthermore, a decrease in the activity of gastric peroxidase and an increase in the activity of gastric superoxide dismutase(s) (SOD) because of piroxicam treatment was attenuated by melatonin pretreatment indicating that the indole possibly exerts its gastroprotective effects through its direct as well as indirect antioxidant activities. Piroxicam 146-155 superoxide dismutase 1 Rattus norvegicus 130-133 15056798-6 2004 Inhibition of mitogen-activated protein kinase kinase (MAPKK) and p38 MAPK using PD98059 (20 microM) and SB202190 (5 microM), respectively, attenuated the elevation of COX-2 protein induced by arsenite, whereas physiological concentrations of three COX-2 inhibitors (e.g., NS-398, piroxicam, and aspirin) reduced arsenite-stimulated DNA synthesis. Piroxicam 281-290 mitogen-activated protein kinase 14 Homo sapiens 66-69 15056798-6 2004 Inhibition of mitogen-activated protein kinase kinase (MAPKK) and p38 MAPK using PD98059 (20 microM) and SB202190 (5 microM), respectively, attenuated the elevation of COX-2 protein induced by arsenite, whereas physiological concentrations of three COX-2 inhibitors (e.g., NS-398, piroxicam, and aspirin) reduced arsenite-stimulated DNA synthesis. Piroxicam 281-290 prostaglandin-endoperoxide synthase 2 Homo sapiens 168-173 15009511-7 2004 The results of the present studies also reveal that melatonin may influence the expression of Cu-Zn SOD, catalase, cyclooxygenase as well as alpha-actinin whose levels were found to be altered, following piroxicam treatment. Piroxicam 204-213 superoxide dismutase 1 Rattus norvegicus 94-103 14742249-9 2004 Treatment of PC-3 cells with a COX-1 selective inhibitor, piroxicam, reduced TXA(2) synthesis by approximately 40%, while the COX-2 specific inhibitor NS398 reduced TXA(2) production by approximately 80%. Piroxicam 58-67 mitochondrially encoded cytochrome c oxidase I Homo sapiens 31-36 14659976-8 2004 Myeloperoxidase activity was significantly increased by piroxicam administration. Piroxicam 56-65 myeloperoxidase Homo sapiens 0-15 12791666-7 2003 Additionally, VEGF- and bFGF-induced angiogenesis in vivo was also inhibited by about 50% by NS-398 or piroxicam, and this inhibitory effect was accompanied by decreased expression of CXCR4 on murine endothelial cells. Piroxicam 103-112 vascular endothelial growth factor A Mus musculus 14-19 14566835-0 2003 Piroxicam selectively inhibits the growth of premalignant and malignant human oral cell lines by limiting their progression through the S phase and reducing the levels of cyclins and AP-1. Piroxicam 0-9 cyclin B1 Homo sapiens 171-178 14602784-8 2003 CRH-induced dilation was also significantly reduced in the presence of the nitric oxide synthase inhibitor, N(omega)-nitro-L-arginine methyl ester, or the cyclooxygenase inhibitor, piroxicam. Piroxicam 181-190 corticotropin releasing hormone Homo sapiens 0-3 15573686-0 2004 Effect of piroxicam on matrix metalloproteinase 2 and apoptosis. Piroxicam 10-19 matrix metallopeptidase 2 Mus musculus 23-49 15573686-6 2004 The results of this study show that piroxicam is able to diminish MMP-2 activity and induce apoptosis under in vitro conditions. Piroxicam 36-45 matrix metallopeptidase 2 Mus musculus 66-71 15573686-8 2004 In conclusion, piroxicam is able to induce apoptosis and suppress MMP-2 activity. Piroxicam 15-24 matrix metallopeptidase 2 Mus musculus 66-71 14654930-0 2004 Synergistic action of piroxicam on the eicosapentaenoic acid-induced apoptosis is associated with enhanced down-regulation of anti-apoptotic Bcl-2 expression but not promoted activation of pro-apoptotic Bid protein. Piroxicam 22-31 BCL2 apoptosis regulator Homo sapiens 141-146 14654930-0 2004 Synergistic action of piroxicam on the eicosapentaenoic acid-induced apoptosis is associated with enhanced down-regulation of anti-apoptotic Bcl-2 expression but not promoted activation of pro-apoptotic Bid protein. Piroxicam 22-31 BH3 interacting domain death agonist Homo sapiens 203-206 12791666-7 2003 Additionally, VEGF- and bFGF-induced angiogenesis in vivo was also inhibited by about 50% by NS-398 or piroxicam, and this inhibitory effect was accompanied by decreased expression of CXCR4 on murine endothelial cells. Piroxicam 103-112 fibroblast growth factor 2 Mus musculus 24-28 12791666-7 2003 Additionally, VEGF- and bFGF-induced angiogenesis in vivo was also inhibited by about 50% by NS-398 or piroxicam, and this inhibitory effect was accompanied by decreased expression of CXCR4 on murine endothelial cells. Piroxicam 103-112 chemokine (C-X-C motif) receptor 4 Mus musculus 184-189 12706496-3 2003 Mean chemiluminescence enhanced with lucigenin in the colons from IL10(-/-) mice treated with piroxicam was more than 5-fold higher than that of the control wt group. Piroxicam 94-103 interleukin 10 Mus musculus 66-70 12860547-1 2003 BACKGROUND: Results of previous studies have shown that piroxicam, a cyclooxygenase-1-2 inhibitor, improves the strength of healing ligaments, whereas celecoxib, a cyclooxygenase-2 inhibitor, impairs ligament healing. Piroxicam 56-65 prostaglandin-endoperoxide synthase 1 Rattus norvegicus 69-85 12880292-9 2003 Rhodamine partitioned to the surface and piroxicam partitioned to the interior of large PLG microspheres. Piroxicam 41-50 plasminogen Homo sapiens 88-91 12803085-1 2003 The singlet excited-state quenching of Acridine Orange (AO) by methyl viologen (MV2+) and the non-steroidal anti-inflammatory drug Piroxicam (Prx), incorporated in sodium bis(2-ethylhexyl) sulfosuccinate (AOT)/isooctane/water and Triton X-100 (Trx-100)/cyclohexane-hexanol/water (w/o) microemulsions, was followed by steady- and transient-state fluorescence. Piroxicam 131-140 thioredoxin Homo sapiens 244-247 12803085-1 2003 The singlet excited-state quenching of Acridine Orange (AO) by methyl viologen (MV2+) and the non-steroidal anti-inflammatory drug Piroxicam (Prx), incorporated in sodium bis(2-ethylhexyl) sulfosuccinate (AOT)/isooctane/water and Triton X-100 (Trx-100)/cyclohexane-hexanol/water (w/o) microemulsions, was followed by steady- and transient-state fluorescence. Piroxicam 142-145 thioredoxin Homo sapiens 244-247 12433932-0 2003 NS-398 and piroxicam suppress UVB-induced activator protein 1 activity by mechanisms independent of cyclooxygenase-2. Piroxicam 11-20 Jun proto-oncogene, AP-1 transcription factor subunit Homo sapiens 42-61 12746190-16 2003 In conclusion, piroxicam suppressed the development of large polyps in APC(delta474) mice by inducing apoptosis and inhibiting VEGF expression in interstitial cells of polyps. Piroxicam 15-24 vascular endothelial growth factor A Mus musculus 127-131 12589035-0 2003 Effects of the cyclooxygenase inhibitor, piroxicam, in combination with chemotherapy on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Piroxicam 41-50 prostaglandin-endoperoxide synthase 1 Canis lupus familiaris 15-29 12589035-1 2003 The objectives of this study were: (a) to determine the antitumor activity and toxicity of a cyclooxygenase inhibitor (piroxicam) combined with cisplatin chemotherapy in dogs with naturally-occurring, invasive transitional cell carcinoma (TCC) of the urinary bladder; and (b) to determine the effects of this treatment on prostaglandin E(2) concentration, tumor cell proliferation and apoptosis, and angiogenesis. Piroxicam 119-128 prostaglandin-endoperoxide synthase 1 Canis lupus familiaris 93-107 12433932-4 2003 However, in the present study we found that both piroxicam, a general COX inhibitor, and NS-398, a COX-2 selective inhibitor, effectively suppressed the activation of transcription factor activator protein 1 (AP-1) induced by ultraviolet B (UVB) or 12-O-tetradecanoylphorbol-13-acetate in mouse epidermal JB6 cells. Piroxicam 49-58 jun proto-oncogene Mus musculus 188-207 12433932-4 2003 However, in the present study we found that both piroxicam, a general COX inhibitor, and NS-398, a COX-2 selective inhibitor, effectively suppressed the activation of transcription factor activator protein 1 (AP-1) induced by ultraviolet B (UVB) or 12-O-tetradecanoylphorbol-13-acetate in mouse epidermal JB6 cells. Piroxicam 49-58 jun proto-oncogene Mus musculus 209-213 12433932-6 2003 UVB significantly increased AP-1 activity in Cox-2(-/-) fibroblasts transfected with an AP-1 luciferase reporter gene, and this increase was blocked by NS-389 or piroxicam. Piroxicam 162-171 Jun proto-oncogene, AP-1 transcription factor subunit Homo sapiens 28-32 12433932-6 2003 UVB significantly increased AP-1 activity in Cox-2(-/-) fibroblasts transfected with an AP-1 luciferase reporter gene, and this increase was blocked by NS-389 or piroxicam. Piroxicam 162-171 mitochondrially encoded cytochrome c oxidase II Homo sapiens 45-50 12433932-6 2003 UVB significantly increased AP-1 activity in Cox-2(-/-) fibroblasts transfected with an AP-1 luciferase reporter gene, and this increase was blocked by NS-389 or piroxicam. Piroxicam 162-171 Jun proto-oncogene, AP-1 transcription factor subunit Homo sapiens 88-92 12433932-7 2003 In JB6, Cox-2(-/-), or wild-type Cox-2(+/+) cells, both NS-398 and piroxicam inhibited UVB-induced phosphorylation of c-Jun NH(2)-terminal kinases, the kinases that activate the AP-1/c-Jun complex. Piroxicam 67-76 mitochondrially encoded cytochrome c oxidase II Homo sapiens 8-13 12433932-7 2003 In JB6, Cox-2(-/-), or wild-type Cox-2(+/+) cells, both NS-398 and piroxicam inhibited UVB-induced phosphorylation of c-Jun NH(2)-terminal kinases, the kinases that activate the AP-1/c-Jun complex. Piroxicam 67-76 mitochondrially encoded cytochrome c oxidase II Homo sapiens 33-38 12433932-7 2003 In JB6, Cox-2(-/-), or wild-type Cox-2(+/+) cells, both NS-398 and piroxicam inhibited UVB-induced phosphorylation of c-Jun NH(2)-terminal kinases, the kinases that activate the AP-1/c-Jun complex. Piroxicam 67-76 Jun proto-oncogene, AP-1 transcription factor subunit Homo sapiens 178-182 12433932-8 2003 Based on our results, we propose that the inhibition of AP-1 activity by COX-2 inhibitors NS-398 or piroxicam may occur by a mechanism that is independent of COX-2. Piroxicam 100-109 Jun proto-oncogene, AP-1 transcription factor subunit Homo sapiens 56-60 12510868-10 2002 Pretreatment with piroxicam (0.2-2.0 mg/kg), a COX-1 inhibitor, considerably diminished the nicotine-induced ACTH and corticosterone secretion in control and crowded rats. Piroxicam 18-27 cytochrome c oxidase I, mitochondrial Rattus norvegicus 47-52 12202939-1 2002 The purpose of this study is to show whether selective (celecoxib) and non-selective (piroxicam) inhibitors of COX-2 can alter the morphological and functional changes after the release of a 24 h complete ureteric obstruction in tissue from solitary rat kidney. Piroxicam 86-95 cytochrome c oxidase II, mitochondrial Rattus norvegicus 111-116 12189186-6 2002 Calcium chloride, DFMO, piroxicam and sulindac administered for 7 days decreased the mitotic index and reduced the protein and mRNA levels of c-myc in colon tumors. Piroxicam 24-33 MYC proto-oncogene, bHLH transcription factor Rattus norvegicus 142-147 12189186-7 2002 Calcium chloride, DFMO and piroxicam increased the protein and mRNA levels of p16 and along with sulindac increased the protein level of p27, but not its mRNA. Piroxicam 27-36 cyclin-dependent kinase inhibitor 2A Rattus norvegicus 78-81 12189186-7 2002 Calcium chloride, DFMO and piroxicam increased the protein and mRNA levels of p16 and along with sulindac increased the protein level of p27, but not its mRNA. Piroxicam 27-36 cyclin-dependent kinase inhibitor 1B Rattus norvegicus 137-140 12036908-6 2002 In DMH-treated animals, long-term treatment with this chemopreventive agent, piroxicam, reduced colon carcinoma incidence and multiplicity in both p53(val135/wt) or p53(wt/wt) mice but did not affect the formation of uterine sarcomas, lung adenomas, or hepatomas. Piroxicam 77-86 transformation related protein 53, pseudogene Mus musculus 147-150 12180128-5 2002 Both oxicams produced a similar extent of the gastric mucosal damage and a significant decrease in PGE2 synthesis, however only piroxicam induced an increase of both myeloperoxidase (MPO) activity and tumor necrosis factor (TNF)-alpha content in the gastric mucosa, indicating that neutrophil-derived free radicals were involved in gastric injury. Piroxicam 128-137 myeloperoxidase Rattus norvegicus 166-181 12180128-5 2002 Both oxicams produced a similar extent of the gastric mucosal damage and a significant decrease in PGE2 synthesis, however only piroxicam induced an increase of both myeloperoxidase (MPO) activity and tumor necrosis factor (TNF)-alpha content in the gastric mucosa, indicating that neutrophil-derived free radicals were involved in gastric injury. Piroxicam 128-137 myeloperoxidase Rattus norvegicus 183-186 12180128-5 2002 Both oxicams produced a similar extent of the gastric mucosal damage and a significant decrease in PGE2 synthesis, however only piroxicam induced an increase of both myeloperoxidase (MPO) activity and tumor necrosis factor (TNF)-alpha content in the gastric mucosa, indicating that neutrophil-derived free radicals were involved in gastric injury. Piroxicam 128-137 tumor necrosis factor Rattus norvegicus 201-234 12063169-6 2002 Probenecid, piroxicam, octanoate and citrinin inhibited OTA uptake by hOAT4 in a competitive manner (K(i)=44.4-336.4 microM), with the following order of potency: probenecid > piroxicam > octanoate >citrinin. Piroxicam 12-21 solute carrier family 22 member 11 Homo sapiens 70-75 12063169-6 2002 Probenecid, piroxicam, octanoate and citrinin inhibited OTA uptake by hOAT4 in a competitive manner (K(i)=44.4-336.4 microM), with the following order of potency: probenecid > piroxicam > octanoate >citrinin. Piroxicam 179-188 solute carrier family 22 member 11 Homo sapiens 70-75 12036908-6 2002 In DMH-treated animals, long-term treatment with this chemopreventive agent, piroxicam, reduced colon carcinoma incidence and multiplicity in both p53(val135/wt) or p53(wt/wt) mice but did not affect the formation of uterine sarcomas, lung adenomas, or hepatomas. Piroxicam 77-86 transformation related protein 53, pseudogene Mus musculus 165-168 12020867-3 2002 The COX-2 preferring inhibitor, NS-398 (60 microg) significantly reversed tactile allodynia 2 h following injection but this anti-allodynic effect did not last greater than 24 h. Surprisingly, the non-selective COX inhibitor, piroxicam (60 microg) was without effect. Piroxicam 226-235 mitochondrially encoded cytochrome c oxidase II Homo sapiens 4-9 12120902-11 2002 Pretreatment with piroxicam (0.2-2.0 mg/kg), a COX-1 inhibitor, considerably impaired the nicotine-induced ACTH and corticosterone secretion. Piroxicam 18-27 cytochrome c oxidase I, mitochondrial Rattus norvegicus 47-52 11484831-6 2001 Naproxen, tiaprofenic acid and piroxicam caused a decrease in GST activity at therapeutic doses. Piroxicam 31-40 glutathione S-transferase kappa 1 Homo sapiens 62-65 12020690-9 2002 The highest cyclooxygenase-2 expression was found with piroxicam and the lowest expression was with celecoxib. Piroxicam 55-64 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 12-28 11809678-0 2002 Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Piroxicam 41-50 prostaglandin-endoperoxide synthase 1 Canis lupus familiaris 15-29 11809678-3 2002 Piroxicam caused reduction in tumor volume in 12 of 18 dogs, and this was strongly associated with induction of apoptosis (Fisher"s exact test P < 0.015) and reduction in urine basic fibroblast growth factor concentration. Piroxicam 0-9 fibroblast growth factor 2 Canis lupus familiaris 180-210 11764219-4 2001 We investigated the possible effects of 3 different nonsteroidal antiinflammatory drugs (NSAID; aceclofenac, piroxicam, aspirin) on IL-1Ra and NO production in human articular chondrocytes. Piroxicam 109-118 interleukin 1 receptor antagonist Homo sapiens 132-138 11901091-3 2002 To this end, the kinetic profiles of three model CYP2C9 substrates (flurbiprofen, naproxen, and piroxicam) were studied using purified CYP2C9*1 (wild-type) and variants involving active site amino acid changes, including the naturally occurring variants CYP2C9*3 (Leu359) and CYP2C9*5 (Glu360) and the man-made mutant CYP2C9 F114L. Piroxicam 96-105 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 49-55 11901091-4 2002 CYP2C9*1 (wild-type) metabolized each of the three compounds with a distinctive profile reflective of typical hyperbolic (flurbiprofen), biphasic (naproxen), and substrate inhibition (piroxicam) kinetics. Piroxicam 184-193 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 0-6 11901091-5 2002 CYP2C9*3 metabolism was again hyperbolic for flurbiprofen, of a linear form for naproxen (no saturation noted), and exhibited substrate inhibition with piroxicam. Piroxicam 152-161 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 0-6 11901091-6 2002 CYP2C9*5-mediated metabolism was hyperbolic for flurbiprofen and piroxicam but linear with respect to naproxen turnover. Piroxicam 65-74 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 0-6 11809688-11 2002 Furthermore, treatment with piroxicam results in significantly lower [Ca(2+)](i) in tumors, and this effect is attenuated by concomitant treatment with the EP1/EP3 receptor agonist 17-phenyl-trinor-PGE(2). Piroxicam 28-37 prostaglandin E receptor 1 (subtype EP1) Mus musculus 156-172 16206787-11 2002 Piroxicam, meloxicam, and carprofen had COX-2 selectivity. Piroxicam 0-9 cytochrome c oxidase subunit II Canis lupus familiaris 40-45 11195457-16 2000 Interestingly, piroxicam was similarly effective in inhibiting colon tumor formation by DMH in mice with or without a mutation in the p53 tumor suppressor gene. Piroxicam 15-24 transformation related protein 53, pseudogene Mus musculus 134-137 11208911-12 2001 Instead, piroxicam and NS-398-induced phosphorylation through ERK pathway may contribute to the increased neuronal survival. Piroxicam 9-18 Eph receptor B1 Rattus norvegicus 62-65 10766173-15 2000 Apc(min)/+ progeny of pregnant dams treated with piroxicam and/or DFMO were reduced in number and their ratio to Apc+/+ progeny was decreased to approximately 0.28:1. Piroxicam 49-58 APC, WNT signaling pathway regulator Mus musculus 0-3 10970676-6 2000 Treatment of the mice with the selective COX1 inhibitor, piroxicam, attenuated the hypophagic responses to IL-1 and LPS. Piroxicam 57-66 cytochrome c oxidase I, mitochondrial Mus musculus 41-45 10970676-6 2000 Treatment of the mice with the selective COX1 inhibitor, piroxicam, attenuated the hypophagic responses to IL-1 and LPS. Piroxicam 57-66 interleukin 1 complex Mus musculus 107-111 10766173-0 2000 Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos. Piroxicam 37-46 APC, WNT signaling pathway regulator Mus musculus 88-91 10766173-15 2000 Apc(min)/+ progeny of pregnant dams treated with piroxicam and/or DFMO were reduced in number and their ratio to Apc+/+ progeny was decreased to approximately 0.28:1. Piroxicam 49-58 APC, WNT signaling pathway regulator Mus musculus 113-116 11021739-3 2000 The purpose of this study was to determine whether cisplatin combined with the cox-inhibitor piroxicam would induce remission more frequently than cisplatin alone in a relevant animal model of human invasive TCC. Piroxicam 93-102 prostaglandin-endoperoxide synthase 1 Canis lupus familiaris 79-82 10718662-1 2000 A simple, HPLC method was developed to estimate meloxicam (COX-2 inhibitor) using piroxicam as the internal standard. Piroxicam 82-91 mitochondrially encoded cytochrome c oxidase II Homo sapiens 59-64 10381057-16 1999 Aspirin and piroxicam were about 8 times more active against COX-1 than COX-2, indomethacin was 7 times more active, and diclofenac was an equipotent inhibitor of COX-1 and COX-2. Piroxicam 12-21 mitochondrially encoded cytochrome c oxidase I Homo sapiens 61-66 10447951-9 1999 This, in turn, suggests that the previously observed antagonistic effects of aspartame and piroxicam are more likely due to their prevention of OA binding to human serum albumin than to PheRS, which is in agreement with binding studies as well as with preliminary simulations performed in our laboratory. Piroxicam 91-100 phenylalanyl-tRNA synthetase subunit beta Homo sapiens 186-191 11153163-10 2000 COX-1 was more inhibited by indomethacin and piroxicam and COX-2 by 6-MNA (active metabolite of nabumetone), diclofenac and ibuprofen. Piroxicam 45-54 mitochondrially encoded cytochrome c oxidase I Homo sapiens 0-5 10567199-4 1999 RIHP and fractional excretion of sodium (FE(Na)) were measured before and after direct renal interstitial volume expansion in control rats (n=7), rats infused with the COX-1 inhibitor piroxicam (n=6, 1.5 mg/kg), and rats infused with the COX-2 inhibitors NS-398 (n=5, 1.5 mg/kg) and meloxicam (n=6, 0.3 mg/kg). Piroxicam 184-193 cytochrome c oxidase I, mitochondrial Rattus norvegicus 168-173 10567199-11 1999 Infusion of piroxicam but not NS-398 or meloxicam blunted the natriuretic response to increased renal interstitial hydrostatic pressure, suggesting that the natriuretic response to increased blood pressure may be preserved during inhibition of COX-2. Piroxicam 12-21 cytochrome c oxidase II, mitochondrial Rattus norvegicus 244-249 10457081-15 1999 Piroxicam pretreatment abolished the Isc response to alpha-methyl-5-HT but not to 5-NOT, indicating that the 5-HT2B-mediated response, but not the 5-HT1B-mediated response, is dependent on prostaglandin synthesis. Piroxicam 0-9 5-hydroxytryptamine receptor 2B Rattus norvegicus 109-115 10336520-3 1999 Piroxicam, which has been shown to prevent the nephrotoxicity of OTA, inhibited OAT1-mediated uptake of OTA. Piroxicam 0-9 solute carrier family 22 (organic anion transporter), member 6 Mus musculus 80-84 10381057-16 1999 Aspirin and piroxicam were about 8 times more active against COX-1 than COX-2, indomethacin was 7 times more active, and diclofenac was an equipotent inhibitor of COX-1 and COX-2. Piroxicam 12-21 mitochondrially encoded cytochrome c oxidase II Homo sapiens 72-77 10381057-16 1999 Aspirin and piroxicam were about 8 times more active against COX-1 than COX-2, indomethacin was 7 times more active, and diclofenac was an equipotent inhibitor of COX-1 and COX-2. Piroxicam 12-21 mitochondrially encoded cytochrome c oxidase I Homo sapiens 163-168 10381057-16 1999 Aspirin and piroxicam were about 8 times more active against COX-1 than COX-2, indomethacin was 7 times more active, and diclofenac was an equipotent inhibitor of COX-1 and COX-2. Piroxicam 12-21 mitochondrially encoded cytochrome c oxidase II Homo sapiens 173-178 10370210-1 1999 Solid dispersions of piroxicam were prepared with polyvinylpyrrolidone (PVP) K-17 PF and PVP K-90 by solvent method. Piroxicam 21-30 keratin 17 Homo sapiens 77-81 10709674-3 1999 As discussed above, all six potential chemopreventive agents, aspirin, 2-CPR, DFMO, 4-HPR, piroxicam, and 9-cis-retinoic acid, decreased the level of AOM-induced ACF. Piroxicam 91-100 ACF Homo sapiens 162-165 10091284-9 1999 In contrast piroxicam and indomethacin, which drugs have a much higher potency against COX-1 than against COX-2, are amongst those with the highest gastrointestinal toxicity. Piroxicam 12-21 mitochondrially encoded cytochrome c oxidase I Homo sapiens 87-92 10091284-9 1999 In contrast piroxicam and indomethacin, which drugs have a much higher potency against COX-1 than against COX-2, are amongst those with the highest gastrointestinal toxicity. Piroxicam 12-21 prostaglandin-endoperoxide synthase 2 Homo sapiens 106-111 9728323-16 1998 The relaxation by naproxen, phenylbutazone, piroxicam and tolmetin is presumably produced by increasing cAMP because the effects of these are antagonized with Rp-cAMPS and H-7, and by pertussis-toxin-sensitive mechanisms. Piroxicam 44-53 calmodulin 2, pseudogene 1 Rattus norvegicus 162-167 9760036-5 1998 In contrast, at 3 h after carrageenin injection, cyclooxygenase 2 inhibitors significantly inhibited all inflammatory parameters however suppression with piroxicam and aspirin was greater, and more pronounced than at 6 h. NS-398 and nimesulide dosing did not reduce thromboxane B2 production from platelets isolated from rats with carrageenin-induced pleurisy, demonstrating that at the doses used, cyclooxygenase 2 inhibitors did not inhibit cyclooxygenase 1, as platelets contain only this isoform. Piroxicam 154-163 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 49-65 9760036-5 1998 In contrast, at 3 h after carrageenin injection, cyclooxygenase 2 inhibitors significantly inhibited all inflammatory parameters however suppression with piroxicam and aspirin was greater, and more pronounced than at 6 h. NS-398 and nimesulide dosing did not reduce thromboxane B2 production from platelets isolated from rats with carrageenin-induced pleurisy, demonstrating that at the doses used, cyclooxygenase 2 inhibitors did not inhibit cyclooxygenase 1, as platelets contain only this isoform. Piroxicam 154-163 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 399-415 9760036-5 1998 In contrast, at 3 h after carrageenin injection, cyclooxygenase 2 inhibitors significantly inhibited all inflammatory parameters however suppression with piroxicam and aspirin was greater, and more pronounced than at 6 h. NS-398 and nimesulide dosing did not reduce thromboxane B2 production from platelets isolated from rats with carrageenin-induced pleurisy, demonstrating that at the doses used, cyclooxygenase 2 inhibitors did not inhibit cyclooxygenase 1, as platelets contain only this isoform. Piroxicam 154-163 prostaglandin-endoperoxide synthase 1 Rattus norvegicus 443-459 9554800-5 1998 In SHR rings with endothelium incubated for 2 h, the contractions caused by angiotensin II were potently inhibited by piroxicam but were unaffected by NS-398. Piroxicam 118-127 angiotensinogen Rattus norvegicus 76-90 9554800-6 1998 Conversely, in rings incubated for 5 h, the hyperresponsiveness to angiotensin II was inhibited to a greater extent by NS-398 than by piroxicam. Piroxicam 134-143 angiotensinogen Rattus norvegicus 67-81 9554800-7 1998 Piroxicam but not NS-398 had a further inhibitory effect on the residual angiotensin II-induced contraction in actinomycin D-treated rings incubated for 5 h. In conclusion, our study shows that long-term incubation leads to hyperresponsiveness to angiotensin II in SHR aorta with endothelium. Piroxicam 0-9 angiotensinogen Rattus norvegicus 73-87 9554800-7 1998 Piroxicam but not NS-398 had a further inhibitory effect on the residual angiotensin II-induced contraction in actinomycin D-treated rings incubated for 5 h. In conclusion, our study shows that long-term incubation leads to hyperresponsiveness to angiotensin II in SHR aorta with endothelium. Piroxicam 0-9 angiotensinogen Rattus norvegicus 247-261 9728323-8 1998 The relaxant effects of naproxen, phenylbutazone, piroxicam and tolmetin were significantly antagonized with pertussis toxin (50 ng ml-1), Rp-cAMPS (100 microM) and H-7 (1 microM). Piroxicam 50-59 calmodulin 2, pseudogene 1 Rattus norvegicus 142-147 9728323-8 1998 The relaxant effects of naproxen, phenylbutazone, piroxicam and tolmetin were significantly antagonized with pertussis toxin (50 ng ml-1), Rp-cAMPS (100 microM) and H-7 (1 microM). Piroxicam 50-59 solute carrier family 9 member A2 Rattus norvegicus 165-168 9809803-3 1998 The cyclo-oxygenase inhibitor, piroxicam (10 microM) and the neuronal conduction blocker, tetrodotoxin (TTX) (0.1 microM) both significantly decreased the SP (0.1 microM) (66% and 36%, respectively) and NKA (1 microM) (64% and 31%, respectively) induced increase in short-circuit current (SCC). Piroxicam 31-40 tachykinin precursor 1 Homo sapiens 203-206 9809803-4 1998 Pretreatment with both piroxicam and TTX totally abolished the SP and NKA response. Piroxicam 23-32 tachykinin precursor 1 Homo sapiens 70-73 9728323-16 1998 The relaxation by naproxen, phenylbutazone, piroxicam and tolmetin is presumably produced by increasing cAMP because the effects of these are antagonized with Rp-cAMPS and H-7, and by pertussis-toxin-sensitive mechanisms. Piroxicam 44-53 solute carrier family 9 member A2 Rattus norvegicus 172-175 9374630-7 1997 However, piroxicam at doses that selectively inhibit PGHS-1 did not have a significant effect on fibroblast proliferation. Piroxicam 9-18 prostaglandin-endoperoxide synthase 1 Homo sapiens 53-59 9706740-6 1998 Endothelin-1 (ET-1) also evoked an increase in Isc that was unaffected by amiloride and was inhibitable by bumetanide, chloride-free solutions, tetrodotoxin, piroxicam, and the ETA receptor antagonist, BQ123. Piroxicam 158-167 endothelin-1 Cavia porcellus 0-12 9706740-6 1998 Endothelin-1 (ET-1) also evoked an increase in Isc that was unaffected by amiloride and was inhibitable by bumetanide, chloride-free solutions, tetrodotoxin, piroxicam, and the ETA receptor antagonist, BQ123. Piroxicam 158-167 endothelin-1 Cavia porcellus 14-18 9391772-11 1997 For patients who require concomitant NSAID and antihypertensive treatment, physicians should be aware that indomethacin, naproxen and piroxicam may be associated with a greater pressor effect than many other NSAIDs, and that antagonism of beta-blockers may be greater than that of vasodilators (including ACE inhibitors and calcium antagonists) and diuretics. Piroxicam 134-143 angiotensin I converting enzyme Homo sapiens 305-308 9489610-5 1998 4 The response to PAF was attenuated by prior application of indomethacin or piroxicam, implicating products of the cyclo-oxygenase pathway in the response. Piroxicam 77-86 PCNA clamp associated factor Homo sapiens 18-21 9322315-5 1997 METHODS: Phospholipase A2 activity was determined, using the degradation of a specific substrate, in the serum and discs of 31 patients (14 treated with acetaminophen and 17 treated with piroxicam) undergoing surgery for sciatica due to lumbar disc herniation. Piroxicam 187-196 phospholipase A2 group IB Homo sapiens 9-25 9350584-10 1997 The amplification by endothelin-1 of the response to (1-100) x 10(-9) mol/l norepinephrine was abolished by blockade of the cyclooxygenase pathway with piroxicam or SO29548. Piroxicam 152-161 endothelin 1 Rattus norvegicus 21-33 9322315-10 1997 Disc phospholipase A2 was significantly correlated with serum phospholipase A2, and was significantly lower in patients treated with piroxicam than in those treated with acetaminophen. Piroxicam 133-142 phospholipase A2 group IB Homo sapiens 5-21 9322315-10 1997 Disc phospholipase A2 was significantly correlated with serum phospholipase A2, and was significantly lower in patients treated with piroxicam than in those treated with acetaminophen. Piroxicam 133-142 phospholipase A2 group IB Homo sapiens 62-78 9257977-4 1997 Piroxicam had no significant effect on granuloma size, significantly decreased histamine forming capacity, CAMP and PGE2 levels. Piroxicam 0-9 cathelicidin antimicrobial peptide Mus musculus 107-111 9223572-8 1997 With this approach, piroxicam had reasonable activity on human PGHS-2 (IC50 = 260-290 nM). Piroxicam 20-29 prostaglandin-endoperoxide synthase 2 Homo sapiens 63-69 9152412-5 1997 The COX-2 inhibitors NS-398 and nimesulide only slightly inhibited PGE2 production, whereas the COX-1/COX-2 inhibitors indomethacin, piroxicam and tenoxicam strongly inhibited PGE2 production. Piroxicam 133-142 cytochrome c oxidase I, mitochondrial Rattus norvegicus 96-101 9152412-5 1997 The COX-2 inhibitors NS-398 and nimesulide only slightly inhibited PGE2 production, whereas the COX-1/COX-2 inhibitors indomethacin, piroxicam and tenoxicam strongly inhibited PGE2 production. Piroxicam 133-142 cytochrome c oxidase II, mitochondrial Rattus norvegicus 102-107 9008610-7 1997 Furthermore, piroxicam significantly decreased the amount of L-selectin shed by cytokine-treated neutrophils, whereas it did not exert this effect on PMA- or A23187-treated neutrophils. Piroxicam 13-22 selectin L Homo sapiens 61-71 9115051-14 1997 Clearances of the two NSAIDs were significantly correlated, suggesting that a common P450 isozyme (most likely CYP2C9, in that piroxicam is a known substrate of this isozyme) may be at least partly involved in the oxidative metabolism of these NSAIDs. Piroxicam 127-136 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 111-117 9083488-2 1997 In subsequent screening in microsomal assays using human COX-1 and COX-2, we discovered that it possessed a selectivity profile for COX-2 superior to piroxicam and other marketed NSAIDs. Piroxicam 150-159 mitochondrially encoded cytochrome c oxidase I Homo sapiens 57-62 9083488-2 1997 In subsequent screening in microsomal assays using human COX-1 and COX-2, we discovered that it possessed a selectivity profile for COX-2 superior to piroxicam and other marketed NSAIDs. Piroxicam 150-159 mitochondrially encoded cytochrome c oxidase II Homo sapiens 67-72 9067546-5 1997 GST activity and GST mu levels were increased (1.2-1.8 x) in oesophagus and small intestine by indomethacin, ibuprofen, piroxicam and sulindac. Piroxicam 120-129 glutathione S-transferase kappa 1 Homo sapiens 0-3 9067546-5 1997 GST activity and GST mu levels were increased (1.2-1.8 x) in oesophagus and small intestine by indomethacin, ibuprofen, piroxicam and sulindac. Piroxicam 120-129 glutathione S-transferase kappa 1 Homo sapiens 17-20 9067546-6 1997 GST alpha levels were induced (1.2-2.8 x) in stomach by piroxicam, in small intestine by indomethacin, ibuprofen, piroxicam and sulindac, and in liver by piroxicam. Piroxicam 56-65 glutathione S-transferase kappa 1 Homo sapiens 0-3 9067546-6 1997 GST alpha levels were induced (1.2-2.8 x) in stomach by piroxicam, in small intestine by indomethacin, ibuprofen, piroxicam and sulindac, and in liver by piroxicam. Piroxicam 114-123 glutathione S-transferase kappa 1 Homo sapiens 0-3 9067546-6 1997 GST alpha levels were induced (1.2-2.8 x) in stomach by piroxicam, in small intestine by indomethacin, ibuprofen, piroxicam and sulindac, and in liver by piroxicam. Piroxicam 114-123 glutathione S-transferase kappa 1 Homo sapiens 0-3 9067546-7 1997 GST pi levels were raised (1.9-3.6 x) in stomach by ibuprofen, ASA, and sulindac, and in small intestine by indomethacin, piroxicam, ASA, and sulindac. Piroxicam 122-131 glutathione S-transferase kappa 1 Homo sapiens 0-3 21533396-8 1997 These results indicate that the administration of piroxicam, a non-steroidal anti-inflammatory drug, and DFMO, a irreversible inhibitor of ornithine decarboxylase, may inhibit selective proliferation of initiated cells containing activated las and/or mutant p53. Piroxicam 50-59 Wistar clone pR53P1 p53 pseudogene Rattus norvegicus 258-261 9008610-8 1997 Piroxicam also decreased the release of gelatinase and lysozyme induced by TNF alpha, but not by PMA. Piroxicam 0-9 tumor necrosis factor Homo sapiens 75-84 9008610-9 1997 Interestingly, piroxicam prevented the conformational changes that beta 2 integrins underwent upon activation of neutrophils: the appearance of the activation epitope of CD11b, detected by the CBRM1/5 MAb, was blocked by piroxicam in TNF alpha-treated neutrophils. Piroxicam 15-24 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 67-73 9008610-9 1997 Interestingly, piroxicam prevented the conformational changes that beta 2 integrins underwent upon activation of neutrophils: the appearance of the activation epitope of CD11b, detected by the CBRM1/5 MAb, was blocked by piroxicam in TNF alpha-treated neutrophils. Piroxicam 15-24 integrin subunit alpha M Homo sapiens 170-175 9008610-9 1997 Interestingly, piroxicam prevented the conformational changes that beta 2 integrins underwent upon activation of neutrophils: the appearance of the activation epitope of CD11b, detected by the CBRM1/5 MAb, was blocked by piroxicam in TNF alpha-treated neutrophils. Piroxicam 15-24 tumor necrosis factor Homo sapiens 234-243 9008610-9 1997 Interestingly, piroxicam prevented the conformational changes that beta 2 integrins underwent upon activation of neutrophils: the appearance of the activation epitope of CD11b, detected by the CBRM1/5 MAb, was blocked by piroxicam in TNF alpha-treated neutrophils. Piroxicam 221-230 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 67-73 9008610-9 1997 Interestingly, piroxicam prevented the conformational changes that beta 2 integrins underwent upon activation of neutrophils: the appearance of the activation epitope of CD11b, detected by the CBRM1/5 MAb, was blocked by piroxicam in TNF alpha-treated neutrophils. Piroxicam 221-230 integrin subunit alpha M Homo sapiens 170-175 9008610-9 1997 Interestingly, piroxicam prevented the conformational changes that beta 2 integrins underwent upon activation of neutrophils: the appearance of the activation epitope of CD11b, detected by the CBRM1/5 MAb, was blocked by piroxicam in TNF alpha-treated neutrophils. Piroxicam 221-230 tumor necrosis factor Homo sapiens 234-243 9008610-10 1997 Moreover, in chemokine-treated T lymphocytes, the expression of activation epitopes on beta 1 integrins was also diminished by piroxicam. Piroxicam 127-136 integrin subunit beta 1 Homo sapiens 87-103 9067636-4 1997 Addition of the cyclooxygenase inhibitors indomethacin (10 microM) or piroxicam (20 microM) slightly increased expression of CD11b and CD18 in cells differentiated with RA, but did not alter expression of surface antigens in cells treated with 1,25-D3. Piroxicam 70-79 integrin subunit alpha M Homo sapiens 125-130 9067636-4 1997 Addition of the cyclooxygenase inhibitors indomethacin (10 microM) or piroxicam (20 microM) slightly increased expression of CD11b and CD18 in cells differentiated with RA, but did not alter expression of surface antigens in cells treated with 1,25-D3. Piroxicam 70-79 integrin subunit beta 2 Homo sapiens 135-139 8881817-8 1996 SNP induced delta SCC was also significantly reduced by piroxicam (mean (SEM)) 10(-5)M (57.9 (11.9)%), nordihydroguaretic acid 10(-4)M (48.0 (12.9)%), tetrodotoxin (TTX 10(-6)M, 52.3 (9.1)%), and practically abolished by TTX and piroxicam together (96.8 (3.3)%). Piroxicam 56-65 serpin family B member 3 Homo sapiens 18-21 8881817-8 1996 SNP induced delta SCC was also significantly reduced by piroxicam (mean (SEM)) 10(-5)M (57.9 (11.9)%), nordihydroguaretic acid 10(-4)M (48.0 (12.9)%), tetrodotoxin (TTX 10(-6)M, 52.3 (9.1)%), and practically abolished by TTX and piroxicam together (96.8 (3.3)%). Piroxicam 229-238 serpin family B member 3 Homo sapiens 18-21 7818568-12 1995 CONCLUSION: Tenidap was differentiated from piroxicam by lower levels of acute-phase proteins, ESR, and IL-6 after tenidap treatment. Piroxicam 44-53 interleukin 6 Homo sapiens 104-108 7488730-0 1995 Carrageenan oedema and spinal Fos-LI neurones are reduced by piroxicam in the rat. Piroxicam 61-70 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 30-33 7488730-5 1995 The effects of piroxicam on the number of spinal Fos-LI neurones and on ankle oedema were positively correlated. Piroxicam 15-24 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 49-52 7789532-0 1995 Selective preservation of protein kinase C-zeta in the chemoprevention of azoxymethane-induced colonic tumors by piroxicam. Piroxicam 113-122 protein kinase C, zeta Rattus norvegicus 26-47 7789532-5 1995 The present studies demonstrate that dietary piroxicam selectively preserved the expression of protein kinase C-zeta in azoxymethane-induced tumors; suggesting that this is at least one mechanism involved in this agent"s chemopreventive actions in this organ. Piroxicam 45-54 protein kinase C, zeta Rattus norvegicus 95-116 8631000-0 1996 Chemoprevention of spontaneous intestinal adenomas in the Apc Min mouse model by the nonsteroidal anti-inflammatory drug piroxicam. Piroxicam 121-130 APC, WNT signaling pathway regulator Mus musculus 58-61 7575694-7 1995 The decrease in SAA concentrations was also significantly greater at weeks 4 and 24 in the tenidap-treated group than in the hydroxychloroquine-plus-piroxicam-treated group. Piroxicam 149-158 serum amyloid A1 cluster Homo sapiens 16-19 7575694-8 1995 Significant reductions in plasma IL-6 levels were observed at weeks 4, 12, and 24 within the tenidap group, and at week 24 within the hydroxychloroquine-plus-piroxicam-treated group. Piroxicam 158-167 interleukin 6 Homo sapiens 33-37 8575109-9 1995 Topical application of 1 nmol/L AII reduced blood flow through outer medullary descending vasa recta by 22 +/- 6% in untreated kidneys and by 24 +/- 7% in piroxicam-treated kidneys. Piroxicam 155-164 angiotensinogen Rattus norvegicus 32-35 7647987-11 1995 EGF responses either in the presence or absence of ITF were also significantly reduced (84% and 66% respectively) by the cyclo-oxygenase inhibitor, piroxicam, therefore implicating prostaglandins as mediators of EGF-stimulated anion secretion. Piroxicam 148-157 epidermal growth factor Homo sapiens 0-3 7647987-11 1995 EGF responses either in the presence or absence of ITF were also significantly reduced (84% and 66% respectively) by the cyclo-oxygenase inhibitor, piroxicam, therefore implicating prostaglandins as mediators of EGF-stimulated anion secretion. Piroxicam 148-157 epidermal growth factor Homo sapiens 212-215 7825862-8 1994 Indomethacin, piroxicam, and sulindac sulfide were found to preferentially inhibit PGHS-1. Piroxicam 14-23 prostaglandin-endoperoxide synthase 1 Mus musculus 83-89 7564880-5 1995 However, indomethacin, diclofenac, phenylbutazone, mefenamic acid, naproxen, piroxicam, aspirin and W-7 inhibit, in a concentration-dependent way, the calmodulin-stimulated activity of phosphodiesterase. Piroxicam 77-86 calmodulin 1 Rattus norvegicus 151-161 7699636-5 1994 The culture medium of treated chondrocytes showed decreased fibrinolytic activity when compared with untreated controls, while PAI activity was increased in both SF chondrocyte culture medium following piroxicam treatment. Piroxicam 202-211 serpin family E member 1 Homo sapiens 127-130 7699636-8 1994 Thus piroxicam reduces both the soluble fibrinolytic activity of human chondrocytes (increase of PAI activity and decrease of released u-PA) and the cell associated u-PA activity (clearance of u-PAR by internalization). Piroxicam 5-14 serpin family E member 1 Homo sapiens 97-100 7699636-8 1994 Thus piroxicam reduces both the soluble fibrinolytic activity of human chondrocytes (increase of PAI activity and decrease of released u-PA) and the cell associated u-PA activity (clearance of u-PAR by internalization). Piroxicam 5-14 plasminogen activator, urokinase Homo sapiens 135-139 7699636-8 1994 Thus piroxicam reduces both the soluble fibrinolytic activity of human chondrocytes (increase of PAI activity and decrease of released u-PA) and the cell associated u-PA activity (clearance of u-PAR by internalization). Piroxicam 5-14 plasminogen activator, urokinase Homo sapiens 165-169 7699636-8 1994 Thus piroxicam reduces both the soluble fibrinolytic activity of human chondrocytes (increase of PAI activity and decrease of released u-PA) and the cell associated u-PA activity (clearance of u-PAR by internalization). Piroxicam 5-14 plasminogen activator, urokinase receptor Homo sapiens 193-198 20692889-6 1994 These results indicate that the cytocidal hepatotoxicity of diclofenac, ketoprofen and piroxicam may be mediated, at least partially, by cytochrome P-450 metabolism. Piroxicam 87-96 cytochrome P450, family 2, subfamily g, polypeptide 1 Rattus norvegicus 137-153 7858871-8 1994 The potentiation of LPS-stimulated release of IL-1-like activity produced by indomethacin, 100 microM, piroxicam, 100 microM, or sodium meclofenamate, 10 microM, was inhibited by prostaglandin E2, (PGE2) 10 ng ml-1. Piroxicam 103-112 interleukin 1 complex Mus musculus 46-50 7858871-10 1994 Aspirin, 100 microM, indomethacin, 100 nM to 10 microM, piroxicam, 1 to 100 microM, and sodium meclofenamate, 10 nM, all potentiated cell-associated IL-1-like activity in LPS- stimulated macrophages. Piroxicam 56-65 interleukin 1 complex Mus musculus 149-153 8064732-5 1994 RESULTS: Piroxicam treatment resulted in elevation of levels of IL-2, depression of IL-1, IL-6, TNF alpha and IFN-gamma, and no consistent effect on IL-4. Piroxicam 9-18 interleukin 2 Homo sapiens 64-68 8064732-5 1994 RESULTS: Piroxicam treatment resulted in elevation of levels of IL-2, depression of IL-1, IL-6, TNF alpha and IFN-gamma, and no consistent effect on IL-4. Piroxicam 9-18 interleukin 1 alpha Homo sapiens 84-88 8064732-5 1994 RESULTS: Piroxicam treatment resulted in elevation of levels of IL-2, depression of IL-1, IL-6, TNF alpha and IFN-gamma, and no consistent effect on IL-4. Piroxicam 9-18 interleukin 6 Homo sapiens 90-94 8064732-5 1994 RESULTS: Piroxicam treatment resulted in elevation of levels of IL-2, depression of IL-1, IL-6, TNF alpha and IFN-gamma, and no consistent effect on IL-4. Piroxicam 9-18 tumor necrosis factor Homo sapiens 96-105 8064732-5 1994 RESULTS: Piroxicam treatment resulted in elevation of levels of IL-2, depression of IL-1, IL-6, TNF alpha and IFN-gamma, and no consistent effect on IL-4. Piroxicam 9-18 interferon gamma Homo sapiens 110-119 8017762-7 1994 NSAIDs such as indomethacin, piroxicam, and sulindac sulfide preferentially inhibit PGHS-1. Piroxicam 29-38 prostaglandin-endoperoxide synthase 1 Mus musculus 84-90 8182646-5 1994 The NSAID effect correlated more consistently with piroxicam downregulation of TNF synthesis than that of IL-1. Piroxicam 51-60 tumor necrosis factor Homo sapiens 79-82 1476192-3 1992 The Isc response to beta-lactoglobulin was reduced by piroxicam, pyrilamine, and cimetidine. Piroxicam 54-63 beta-lactoglobulin Bos taurus 20-38 8140037-4 1993 The increased PGE2 synthesis observed for indomethacin and piroxicam (animals treated for three consecutive days) could be explained by the depression of cytochrome P-450 observed in the same animals. Piroxicam 59-68 cytochrome P450, family 2, subfamily g, polypeptide 1 Rattus norvegicus 154-170 8482447-6 1993 RESULTS: Serosal addition of endothelin 1 evoked a sustained increase in short-circuit current that was significantly reduced by tetrodotoxin or atropine, and virtually abolished by a selective endothelin A receptor antagonist (BQ-123), furosemide, piroxicam, d,I-verapamil, or removal of serosal calcium. Piroxicam 249-258 endothelin 1 Rattus norvegicus 29-41 8472334-8 1993 The AOM-induced expression of biochemically active p21ras was significantly suppressed by dietary DFMO and piroxicam. Piroxicam 107-116 HRas proto-oncogene, GTPase Rattus norvegicus 51-57 8454631-4 1993 Among common NSAIDs tested, indomethacin, sulindac sulfide, and piroxicam preferentially inhibited PGH synthase-1; ibuprofen, flurbiprofen, and meclofenamate inhibited both enzymes with comparable potencies; and 6-methoxy-2-naphthylacetic acid preferentially inhibited PGH synthase-2. Piroxicam 64-73 prostaglandin-endoperoxide synthase 1 Mus musculus 99-113 8454631-4 1993 Among common NSAIDs tested, indomethacin, sulindac sulfide, and piroxicam preferentially inhibited PGH synthase-1; ibuprofen, flurbiprofen, and meclofenamate inhibited both enzymes with comparable potencies; and 6-methoxy-2-naphthylacetic acid preferentially inhibited PGH synthase-2. Piroxicam 64-73 prostaglandin-endoperoxide synthase 2 Mus musculus 269-283 8399066-4 1993 Both INDO and another cyclooxygenase inhibitor, piroxicam, abrogated induction of a protective effect to a subsequent, potentially lethal challenge with TNF. Piroxicam 48-57 tumor necrosis factor Homo sapiens 153-156 8386981-6 1993 Inhibition of carcinogenesis by piroxicam and difluoromethyl ornithine inhibited alpha 1AT expression. Piroxicam 32-41 serpin family A member 1 Homo sapiens 81-90 8213346-4 1993 Intraperitoneal treatment of mice with either 0.64 mg/kg piroxicam or its Cu2+ complexes (0.64 mg/kg piroxicam + 0.12 mg/kg Cu2+) was equally effective in diminishing both the migration of polymorphonuclear leukocytes (PMNL) to the airways and the content of myeloperoxidase activity in the lungs, induced by aerosol challenge with Pseudomonas aeruginosa peptide chemotactins. Piroxicam 57-66 myeloperoxidase Mus musculus 259-274 1476192-7 1992 Piroxicam, cimetidine plus pyrilamine, or a combination of piroxicam, cimetidine, and pyrilamine significantly reduced the release of ACh after beta-lactoglobulin challenge. Piroxicam 59-68 beta-lactoglobulin Bos taurus 144-162 1476192-7 1992 Piroxicam, cimetidine plus pyrilamine, or a combination of piroxicam, cimetidine, and pyrilamine significantly reduced the release of ACh after beta-lactoglobulin challenge. Piroxicam 0-9 beta-lactoglobulin Bos taurus 144-162 2372742-6 1990 The impairment on antipyrine disposition produced by piroxicam has been interpreted as a consequence of a reduction in the activity of hepatic microsomal drug-metabolizing enzymes, particularly the cytochrome P-450 system. Piroxicam 53-62 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 198-214 1384022-0 1992 Effects of piroxicam and ibuprofen on substance P induced chemotaxis of human monocytes and polymorphonuclear cells. Piroxicam 11-20 tachykinin precursor 1 Homo sapiens 38-49 1686661-6 1991 The cyclooxygenase inhibitors, indomethacin and piroxicam, inhibited the increase in Isc produced by ET-3 and indomethacin also abolished the changes in Na+ and Cl- fluxes produced by ET-3. Piroxicam 48-57 endothelin-3 Oryctolagus cuniculus 101-105 1686661-6 1991 The cyclooxygenase inhibitors, indomethacin and piroxicam, inhibited the increase in Isc produced by ET-3 and indomethacin also abolished the changes in Na+ and Cl- fluxes produced by ET-3. Piroxicam 48-57 endothelin-3 Oryctolagus cuniculus 184-188 1873481-3 1991 Infusion of rIL-1 alpha produced a transient increase in serum (PGs) which peaked at 24 to 48 h. This increase was completely inhibited by piroxicam. Piroxicam 139-148 interleukin 1 alpha Rattus norvegicus 12-23 2027111-2 1991 Piroxicam has been shown to downregulate the expression of interleukin 1 (IL-1) associated chondrocyte enzyme inducing activity (catabolin) produced by OA synovium. Piroxicam 0-9 interleukin 1 alpha Homo sapiens 59-78 2027111-2 1991 Piroxicam has been shown to downregulate the expression of interleukin 1 (IL-1) associated chondrocyte enzyme inducing activity (catabolin) produced by OA synovium. Piroxicam 0-9 interleukin 1 beta Homo sapiens 129-138 2027111-4 1991 The piroxicam effect appears due to a selective increase in production of a naturally occurring inhibitor(s) and/or induction of new inhibitor formation acting on chondrocytes at a post-IL-1 receptor level. Piroxicam 4-13 interleukin 1 alpha Homo sapiens 186-190 1823383-7 1991 In the piroxicam group, serum calcium, phosphate, osteocalcin and urinary calcium increased significantly, and PTH and glycosaminoglycan excretion significantly decreased. Piroxicam 7-16 bone gamma-carboxyglutamate protein Homo sapiens 50-61 1823383-7 1991 In the piroxicam group, serum calcium, phosphate, osteocalcin and urinary calcium increased significantly, and PTH and glycosaminoglycan excretion significantly decreased. Piroxicam 7-16 parathyroid hormone Homo sapiens 111-114 2103967-1 1990 The anti-inflammatory and analgesic activity of the beta-cyclodextrin-piroxicam (beta CDP) complex was assessed in a randomized single-blind controlled parallel study vs nabumetone (NAB). Piroxicam 70-79 cut like homeobox 1 Homo sapiens 86-89 1600622-1 1992 Our previous studies have shown that dietary piroxicam, a non-steroidal anti-inflammatory drug (NSAID), and D,L-alpha-difluoromethylornithine (DFMO), an ornithine decarboxylase (ODC) inhibitor, act as potential chemopreventive agents in inhibiting azoxymethane (AOM)-induced colon carcinogenesis in male F344 rats. Piroxicam 45-54 ornithine decarboxylase 1 Rattus norvegicus 153-176 1600622-1 1992 Our previous studies have shown that dietary piroxicam, a non-steroidal anti-inflammatory drug (NSAID), and D,L-alpha-difluoromethylornithine (DFMO), an ornithine decarboxylase (ODC) inhibitor, act as potential chemopreventive agents in inhibiting azoxymethane (AOM)-induced colon carcinogenesis in male F344 rats. Piroxicam 45-54 ornithine decarboxylase 1 Rattus norvegicus 178-181 1662723-5 1991 Piroxicam (10 microM) independently reduced FMLP dependent superoxide anion generation to 63.7 +/- 7.4% (p less than 0.01) of control. Piroxicam 0-9 formyl peptide receptor 1 Homo sapiens 44-48 1726487-1 1991 The interaction of the anti-inflammatory drug, piroxicam, with some naturally occurring polymers-viz gamma-globulin, bovine serum-albumin, bovine synovial fluid and casein was characterized in this study. Piroxicam 47-56 albumin Bos taurus 124-137 1937915-1 1991 Prophylactic administration of Piroxicam (Feldene), a reversible inhibitor of prostaglandin biosynthesis, significantly reduced the occurrence of paralytic signs and the amount of antibodies against myelin basic protein in the model of mild acute experimental allergic encephalomyelitis in the Lewis rat. Piroxicam 31-40 myelin basic protein Rattus norvegicus 199-219 1937915-1 1991 Prophylactic administration of Piroxicam (Feldene), a reversible inhibitor of prostaglandin biosynthesis, significantly reduced the occurrence of paralytic signs and the amount of antibodies against myelin basic protein in the model of mild acute experimental allergic encephalomyelitis in the Lewis rat. Piroxicam 42-49 myelin basic protein Rattus norvegicus 199-219 1706667-5 1990 Antisecretory effects of SS-14 were markedly attenuated by piroxicam and were restored following piroxicam plus either forskolin or vasoactive intestinal polypeptide (VIP). Piroxicam 59-68 somatostatin Rattus norvegicus 25-30 1706667-5 1990 Antisecretory effects of SS-14 were markedly attenuated by piroxicam and were restored following piroxicam plus either forskolin or vasoactive intestinal polypeptide (VIP). Piroxicam 97-106 somatostatin Rattus norvegicus 25-30 2123471-3 1990 However, the LAF activity from lipopolysaccharide (LPS)-treated MNP cultures was increased after Piroxicam (0.1-20 mumol/L) treatment. Piroxicam 97-106 4-hydroxyphenylpyruvic acid dioxygenase Mus musculus 13-16 2109653-0 1990 Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a nonsteroidal antiinflammatory drug with D,L-alpha-difluoromethylornithine, an ornithine decarboxylase inhibitor, in diet. Piroxicam 72-81 ornithine decarboxylase 1 Rattus norvegicus 163-186 2114298-6 1990 The effects of IL-1 were inhibited by removal of Cl- from the bathing solutions, or by indomethacin or piroxicam. Piroxicam 103-112 interleukin 1 alpha Homo sapiens 15-19 2138999-10 1990 These data suggest that piroxicam and indomethacin interfere with postreceptor signaling events specific to PMN stimulation by FMLP. Piroxicam 24-33 formyl peptide receptor 1 Homo sapiens 127-131 2138999-6 1990 Both piroxicam and indomethacin inhibited FMLP-induced upregulation of CD11b, CD11c, and CD35, but neither drug affected the upregulation of these surface molecules induced by C5a or ionomycin. Piroxicam 5-14 formyl peptide receptor 1 Homo sapiens 42-46 2138999-6 1990 Both piroxicam and indomethacin inhibited FMLP-induced upregulation of CD11b, CD11c, and CD35, but neither drug affected the upregulation of these surface molecules induced by C5a or ionomycin. Piroxicam 5-14 integrin subunit alpha M Homo sapiens 71-76 2138999-6 1990 Both piroxicam and indomethacin inhibited FMLP-induced upregulation of CD11b, CD11c, and CD35, but neither drug affected the upregulation of these surface molecules induced by C5a or ionomycin. Piroxicam 5-14 integrin subunit alpha X Homo sapiens 78-83 2138999-6 1990 Both piroxicam and indomethacin inhibited FMLP-induced upregulation of CD11b, CD11c, and CD35, but neither drug affected the upregulation of these surface molecules induced by C5a or ionomycin. Piroxicam 5-14 complement C3b/C4b receptor 1 (Knops blood group) Homo sapiens 89-93 2138999-9 1990 We conclude that piroxicam and indomethacin inhibit FMLP receptor-mediated upregulation of CD11b, CD11c, and CD35 in PMNs, but have no effect on the upregulation of these molecules by ionomycin or C5a. Piroxicam 17-26 formyl peptide receptor 1 Homo sapiens 52-65 2138999-9 1990 We conclude that piroxicam and indomethacin inhibit FMLP receptor-mediated upregulation of CD11b, CD11c, and CD35 in PMNs, but have no effect on the upregulation of these molecules by ionomycin or C5a. Piroxicam 17-26 integrin subunit alpha M Homo sapiens 91-96 2138999-9 1990 We conclude that piroxicam and indomethacin inhibit FMLP receptor-mediated upregulation of CD11b, CD11c, and CD35 in PMNs, but have no effect on the upregulation of these molecules by ionomycin or C5a. Piroxicam 17-26 integrin subunit alpha X Homo sapiens 98-103 2138999-9 1990 We conclude that piroxicam and indomethacin inhibit FMLP receptor-mediated upregulation of CD11b, CD11c, and CD35 in PMNs, but have no effect on the upregulation of these molecules by ionomycin or C5a. Piroxicam 17-26 complement C3b/C4b receptor 1 (Knops blood group) Homo sapiens 109-113 2138999-9 1990 We conclude that piroxicam and indomethacin inhibit FMLP receptor-mediated upregulation of CD11b, CD11c, and CD35 in PMNs, but have no effect on the upregulation of these molecules by ionomycin or C5a. Piroxicam 17-26 complement C5a receptor 1 Homo sapiens 197-200 1982764-1 1990 The effects of piroxicam (40 mg) on the pharmacokinetics of ranitidine (150 mg) and of ranitidine (150 mg bid) on the pharmacokinetics of piroxicam (20 mg) were assessed in two 2-way crossover studies in two groups of 18 healthy male subjects. Piroxicam 138-147 BH3 interacting domain death agonist Homo sapiens 106-109 33233771-6 2020 Acute murine colitis was induced using 4% DSS and chronic colitis was generated in piroxicam-treated IL-10-/- mice. Piroxicam 83-92 interleukin 10 Mus musculus 101-106 34970327-11 2021 In rats with ethanol- or piroxicam-induced ulcers, AETo reduced the ulceration area, elevated mucin level, and the gastroprotective effect was confirmed by histological analysis. Piroxicam 25-34 solute carrier family 13 member 2 Rattus norvegicus 94-99